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S1  Primary somatosensory cortex 
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1 INTRODUCTION 
Pain has a protective function which helps us to avoid further injury and to anticipate 
future harm and therefore has a central role in our lives. However, if pain becomes 
chronic, its regulation becomes essential. Healthy individuals have a number of 
mechanisms to inhibit unnecessary pain and thereby avoid unnecessary suffering. To 
understand those mechanisms in healthy individuals and to find alterations of them in 
patients with chronic pain, may offer paths for treating their pain. The goal of this 
dissertation was to further characterize stress and controllability as two factors that 
contribute to pain regulation. In the following chapters, a number of pain regulatory 
mechanisms will be introduced and previous work on behavioral, neuronal and 
neurochemical aspects will be described. Where possible, alterations in chronic pain 
will be briefly addressed. The effects of stress and control will be discussed in more 
detail. 
1.1 Cognitive and emotional modulation of pain 
The experience of pain is modulated by cognitive and emotional factors. While a 
positive emotional state inhibits the experience of pain, negative emotional states 
increase pain perception (Villemure & Bushnell, 2009). Cognitive factors that 
modulate the perception of pain include the attentional focus of the individual on pain 
(Torta, Legrain, Mouraux, & Valentini, 2017), the predictability (Arntz, van Eck, & de 
Jong, 1991) or controllability (Bräscher, Becker, Hoeppli, & Schweinhardt, 2016) of 
the context in which the individual perceives the pain, and the expectation, which the 
individual has towards a painful stimulus. But especially chronic pain also affects the 
cognitive and emotional processing of an individual. For example, it was shown that 
performance in an attentional task was worse in patients with chronic pain. In this 
study, patients with high chronic pain intensities were particularly impaired, while 
patients with low pain intensities were able to compensate the attentional demands of 
their chronic pain by switching their attention between the cognitive task and the pain 
(Eccleston, 1995). Hence the cognitive and emotional modulation of pain can be 
viewed in a feedback loop between pain, emotion and cognition (Bushnell, Čeko, & 
Low, 2013), see Figure 1. In the following a number of pain modulatory factors are 
discussed, without however claiming completeness. 
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Figure 1: A common theoretical framework illustrating the effects of cognitive and 
emotional factors on pain, reversed effects of pain on cognition and emotional state, 
as well as reciprocal within each domain. Based on (Bushnell et al., 2013). 
 
The attentional modulation of pain has been shown by several studies using 
distraction paradigms. For example, in a study on somatic and visceral pain, an 
auditory and a painful stimulus were presented to the subjects. Subjects were either 
asked to attend to the painful stimulus (attention) or to attend to the auditory stimulus 
(distraction). They showed reduced pain intensity ratings in the distraction condition 
(Dunckley et al., 2007). Other studies used auditory distraction (Boyle, El-Deredy, 
Martínez, Bentley, & Jones, 2008), basic visual stimuli (Miron, Duncan, & Bushnell, 
1989), the Stroop task (Bantick et al., 2002), or a mental arithmetic task (Hodes, 
Howland, Lightfoot, & Cleeland, 1990) to distract their participants and they support 
the result that focusing attention away from the stimulus has analgesic effects. 
Additionally, these studies showed that patients with chronic pain had deficiencies in 
regulating their pain by distracting themselves from the pain (Snijders, Ramsey, 
Koerselman, & van Gijn, 2010). 
A factor that modulates the pain experience before the pain even occurs is the 
expectancy of the individual towards the pain, i.e. whether the individual expects to 
experience high pain or little pain in the future. This was shown in an experiment 
where subjects were trained to expect lower pain intensities when the announcement 
phase of a stimulus was shorter. Subjects subsequently reported lower pain ratings 
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when they expected lower stimulus intensities (Koyama, McHaffie, Laurienti, & 
Coghill, 2005). The expectations towards the pain certainly depend on prior 
experiences of an individual (Dar, Ariely, & Frenk, 1995) and therefore may explain 
part of the inter-individual variation in pain sensitivity (Coghill, McHaffie, & Yen, 
2003). Expectancy and prior learning experiences have further been shown to 
mediate placebo and nocebo responses. Placebo analgesia can be elicited by verbal 
instructions that create expectations of analgesia and recall previous experiences of 
pain relief (Price et al., 1999). Nocebo responses, on the other hand, are elicited by 
verbal instructions that create expectations of hyperalgesia (Colloca, Sigaudo, & 
Benedetti, 2008). 
A factor related to expectancy is the predictability of pain. If pain is experienced 
under predictable conditions, the organism can prepare for the painful event. The 
predictability of the painful stimulus therefore has critical influence on the experience 
of the pain. This was shown in healthy participants, who could tolerate lower pain 
intensities if the intensity of a painful stimulus was not predictable to them (Arntz et 
al., 1991). They perceived pain as more intense and unpleasant when the stimulus 
onset was either not predictable in time or by a predictive cue (Carlsson et al., 2006). 
Hence there are two aspects of predictability that have been shown to modulate pain: 
knowledge about the nature of the painful stimulation (e.g. intensity), and information 
about the timing of the stimulus (e.g. cue or timing) (Miller, 1981). The lack of a 
predictive cue can furthermore enhance the modulation of pain by an emotional 
context. While positive and negative pictures had little influence on the nociceptive 
flexion reflex (NFR) when pain was signaled by a predictive cue, positive pictures 
decreased NFR and negative pictures increased the NFR when this signal was 
lacking (Rhudy, Williams, McCabe, Rambo, & Russell, 2006). 
On the one hand, this interaction between the effect of predictability on pain and the 
effect of the individual’s emotional state on pain shows that emotional modulation of 
pain is not independent of cognitive processing. On the other hand, it was also 
shown that perceived pain intensity and also NFR were modulated by emotional 
pictures (Rhudy, Williams, McCabe, Nguyen, & Rambo, 2005) or emotional auditory 
stimuli (Stancak, Ward, & Fallon, 2013) alone. The enhancement of pain intensity by 
negative emotional pictures is especially pronounced if the pictures depict pain-
relevant cues, such as other people in pain (Godinho, Magnin, Frot, Perchet, & 
Garcia-Larrea, 2006). Emotional modulation of pain is particularly interesting as it has 
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been shown that the analgesic effects of positive emotions are impaired in patients 
with fibromyalgia (Kamping, Bomba, Kanske, Diesch, & Flor, 2013), which may be 
caused by a general deficit in appetitive activation in this group of patients (Rhudy et 
al., 2013). 
1.1.1 Stress-induced analgesia 
A phenomenon that is closely related to pain modulation by emotional context is 
stress. Interestingly stress can either increase pain (stress-induced analgesia, SIA) or 
decrease pain perception (stress-induced hyperalgesia, SIH). Whether stress 
reduces or increases pain perception depends on the arousal level associated with 
stress (Woodhams, Chapman, Finn, Hohmann, & Neugebauer, 2017). Paradigms 
that used negative visual or negative auditory information (Rhudy et al., 2005; 
Stancak et al., 2013) to induce negative emotional states elicit only low to moderate 
arousal levels and tend to exacerbate pain (SIH). On the other hand paradigms that 
induced stress by social isolation (Puglisi-Allegra & Oliverio, 1983), exposure to 
mental arithmetic plus noise (Flor & Grüsser, 1999) or painful electrical stimulation 
(Willer, Dehen, & Cambier, 1981) elicit negative emotions with high arousal levels 
and inhibit pain (SIA). 
Besides the intensity of the stressor, the duration of the stressful event influences the 
way stress modulates pain (Jennings, Okine, Roche, & Finn, 2014). Studies that 
successfully induced SIH used longer stressors, such as separating rats’ pups from 
their mothers for 3 hours a day for 2 weeks (van den Wijngaard et al., 2012) or 
restraint stress for 1 hour and up to 40 days (Gameiro et al., 2006). On the other 
hand studies that successfully induced SIA used shorter stressors, such as stressing 
rats with 3 to 30 minutes of electrical foot shock (Lewis, Cannon, & Liebeskind, 1980) 
or a one-time immobilization of rats for 90 minutes (Costa, Smeraldi, Tassorelli, 
Greco, & Nappi, 2005). This latter study directly compared the effects of long and 
short stress induction on pain by also repeating the immobilization over a period of 7 
days. When using this repetitive long stressor, they found hyperalgesic rather than 
analgesic effects. 
Chronic pain conditions go along with an increased prevalence of comorbid stress-
related disorders such as posttraumatic stress disorder (Vaegter, Andersen, Harvold, 
Andersen, & Graven-Nielsen, 2017), depression or anxiety disorders (Gerhardt et al., 
2011; McWilliams, Cox, & Enns, 2003). Furthermore, a large proportion of patients 
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with fibromyalgia perceive stress as an aggravating factor of their pain (Okifuji & 
Turk, 2002) and show elevated stress reactivity (Thieme, Turk, Gracely, Maixner, & 
Flor, 2015) and an impaired circadian rhythm of blood cortisol levels (Crofford et al., 
2004). It is thus not surprising that those patients also show altered modulation of 
pain by stress. In a study using the “Trierer Social Stress Test“, a standardized 
procedure to induce psychosocial stress, it was shown that patients with fibromyalgia 
displayed a SIH effect on mechanical pain measures, which could not be observed in 
the healthy control sample (Crettaz et al., 2013). However, it should be noted that 
both, the patients and the control sample, showed SIH when tested with thermal pain 
measures. Therefore the exact mechanisms of stress modulation in chronic pain 
remain to be elucidated. Additional support for altered pain modulation by stress in 
chronic pain comes from a study that induced pain and stress by a 1 hour mental 
task that provoked more head and neck pain in patients with fibromyalgia compared 
to healthy participants (Nilsen et al., 2007). Conclusions from the latter study about 
mechanisms are, however, limited as pain induction and stress induction are not 
separable in the study design. 
1.1.2 Controllability 
The ability to control negative events is essential for the well-being of an individual 
and uncontrollable environments have been associated with mental disorders such 
as depression (Abramson, Seligman, & Teasdale, 1978) or post-traumatic stress 
disorder (Foa, Zinbarg, & Rothbaum, 1992). Early studies on the effects of 
uncontrollable electric stimulation were done in dogs, which learned to jump over a 
barrier to avoid painful stimulation. Interestingly this relatively easily learned 
association was not acquired by dogs that were previously exposed to uncontrollable 
painful stimulation (Seligman & Maier, 1967). This finding was later reproduced in a 
similar manner in human studies and led to the formulation of the theory of learned 
helplessness of depression. Depressive patients believe that they cannot control their 
environment, experience themselves as incompetent and therefore fail to show 
adaptive behavior to regulate their environment (Seligman, 1972). Although more 
recent data suggest that this passive behavior in the presence of painful stimulation 
is not learned but rather the default response to such events, the theory of learned 
helplessness has critically influenced therapy, clinical research as well as animal 
models of depressive disorders (Maier & Seligman, 2016). 
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Already the early studies on controllability were using painful stimulation, which was 
either controllable or not. Besides the effects on depression, also the effects of 
control on the painful experience itself were systematically studied. Interestingly, 
those studies showed that the analgesic effect of control seems to depend on a 
number of factors. The mere perception of control over a painful stimulation has 
analgesic effects, however, if the control is actually exerted, the analgesic effect is 
larger (Mohr, Leyendecker, Petersen, & Helmchen, 2012). The control action has to 
be exerted by the individual him- or herself and may not be exerted by a third person. 
Therefore external control does not reduce pain sensation, whereas internal control 
does (Wiech et al., 2006). These findings can in part be explained by the higher 
degree of predictability in a context where control is exerted by the individual. 
Whether the individual had control over a painful stimulus in the past and therefore 
expects to have control in the future, affects the emotional response to pain but not 
the pain sensation itself. In an experiment where one group had control over a painful 
stimulus and subsequently lost control, those who lost control showed higher fear of 
the painful stimulation compared to a group who had not experienced prior control 
over the stimulation. However, the groups showed no differences in pain 
unpleasantness ratings. Additionally, the performance in a secondary task decreased 
for participants that previously had control over the pain, which speaks in favor of an 
increased attentional focus on the painful stimulation when control is lost (Crombez, 
Eccleston, De Vlieger, Van Damme, & De Clercq, 2008). 
For cognitive factors such as perceived control, not only the actual control, but also 
the perceived control is important. Hence the appraisal of the context as controllable 
or not is as important as really being able to control the painful experience. The 
general belief that pain can be controlled by one’s own actions (i.e. an internal locus 
of control) has been associated with lower depression levels in patients with chronic 
pain (Wong & Anitescu, 2017) and the general belief that pain is determined by 
factors such as chance or other persons mediates therapy outcomes such as 
functional disability and suffering in patients with chronic pain (Pereira, Roios, & 
Pereira, 2017). Therefore, the effect of control is determined by an interaction of 
personal control beliefs and the actual potential to change the painful context. 
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1.2 Neuronal correlates of pain and pain modulation 
1.2.1 Ascending nociceptive pathways 
Painful stimulation is associated with activation in brain areas such as the primary 
(S1) and secondary (S2) somatosensory cortex, the anterior cingulate cortex (ACC), 
the insula, the prefrontal cortex (PFC), the amygdala, the thalamus and the 
periaqueductal grey (PAG) (Duerden & Albanese, 2013). Different parts of this 
network process different aspects of the pain experience. The sensory aspects of 
pain, such as intensity, location (Vierck, Whitsel, Favorov, Brown, & Tommerdahl, 
2013), or duration of the pain (Khoshnejad et al., 2017) seem to be primarily encoded 
in S1 and S2. The ACC on the other hand encodes primarily emotional aspects of 
pain such as its unpleasantness (Bliss, Collingridge, Kaang, & Zhuo, 2016). The 
insula has been proposed to be involved in both, sensory and affective processing of 
nociceptive information, whereby the posterior part of the insular cortex 
predominantly encodes the sensory pain dimension and the anterior part 
predominantly encodes the affective-motivational dimension (Lu et al., 2016). 
A central gateway of incoming nociceptive information is the thalamus, which acts as 
a gateway in two parallel ascending nociceptive pathways. The medial pathway 
relays nociceptive information via nuclei in the lateral thalamus to the ACC. This 
pathway has been proposed to process the affective component of pain. The lateral 
pathway on the other hand relays nociceptive information via the lateral thalamus to 
the somatosensory cortices. This pathway has been suggested to be involved in the 
processing of the sensory component of pain. In accordance with its double role in 
sensory and affective processing, the insula seems to play a special role in those 
pathways and receives input from the lateral system, but also projects to the limbic 
areas, such as the amygdala (Almeida, Roizenblatt, & Tufik, 2004; Treede, Kenshalo, 
Gracely, & Jones, 1999). 
The amygdala, known for its role in emotional learning (LeDoux, 1992), receives 
nociceptive inputs from the dorsal horn of the spinal cord via the parabrachial area as 
well as from thalamic pathways. Nociceptive inputs are predominantly received by 
the basolateral part of the amygdala where they are processed and forwarded as 
affect-related information to the central nucleus of the amygdala. The central nucleus 
on the other hand modulates pain behavior through projections to descending pain 
control centers in the brainstem (Neugebauer, 2015). 
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It is important to note that activity in the above described pain-related areas is not a 
specific response to painful stimulation, as it has been shown that the network of 
brain areas involved in pain processing may also be activated by non-painful 
stimulation (Iannetti & Mouraux, 2010). However, although not specific for pain, the 
modulation of responses within this network offers potential for pain modulation. 
1.2.2 Descending modulation of pain 
One of the first findings on the inhibition of pain was that pain behavior in response to 
mechanical pain stimulation could be blocked by electrical stimulation in the PAG of 
rats (Reynolds, 1969). The PAG receives nociceptive input from ascending pain 
pathways, but also cortical input from the frontal and insular cortex, the amygdala, 
and the hypothalamus and additionally has projections to the rostral ventromedial 
medulla (RVM) (Basbaum & Fields, 1984). The RVM is the major source of 
projections to the dorsal horn of the spinal cord where the first synapses of ascending 
pain pathways are, and therefore transmission of nociceptive information to higher 
order centers can be inhibited or enhanced (Millan, 2002). 
The high level of interconnectivity of the PAG with cortical areas makes the PAG-
RVM system one of the most important targets of the cortical modulation of pain. The 
PAG and RVM therefore act as relay stations for cortical descending pain control 
(Stamford, 1995). However, other pathways, such as the dorsal reticular nucleus and 
ventrolateral medulla have also been implicated in descending pain control 
(Heinricher, Tavares, Leith, & Lumb, 2009). 
How higher order processes in the cortex modulate these systems of descending 
pain control depends on the nature of the process. For example, attention seems to 
modulate activity in the insula and somatosensory cortex, while emotional modulation 
of pain primarily depends on activity in the ACC (Bushnell et al., 2013). This was, for 
example, shown in a study where auditory distraction led to a decreased pain-related 
activity in somatosensory cortex (Dunckley et al., 2007). Imaging of the PAG further 
confirmed activation of descending control systems during distraction (Tracey et al., 
2002) and placebo-induced PAG activation during anticipation of pain (Wager et al., 
2004). The role of the ACC in the emotional modulation of pain was shown by using 
pleasant odors that not only reduced the experience of pain unpleasantness, but also 
decreased pain-related activation of the ACC. Importantly, ACC activity in this study 
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was also associated with activity in the PAG, which confirms the activation of 
descending pathways by emotional modulation of pain (Villemure & Bushnell, 2009). 
A high overlap between pathways that activate descending modulation and placebo 
analgesia is implied by the fact that ACC activation is not only modulated by 
emotional context, but that ACC activation in response to a painful stimulation was 
reduced in a placebo condition, and this ACC hypoactivation was related to 
increased activity in the dorsolateral prefrontal (dlPFC) and orbitofrontal cortex (OFC) 
in an anticipation phase before the stimulation (Wager et al., 2004). 
The function of the PFC in pain processing is manifold and includes the cognitive 
evaluation of the nociceptive information as well as endogenous pain regulation 
(Seminowicz & Moayedi, 2017). Especially the dlPFC modulates pain via attentional 
networks and was associated with a down-regulation of the medial thalamic pathway 
and a modulation of pain-related activation in the anterior insula, and thereby 
reducing the perceived intensity and unpleasantness of painful stimulation (Lorenz, 
Minoshima, & Casey, 2003; Peyron et al., 1999).  
1.2.3 Neurochemical correlates of the descending modulation of pain 
The most commonly known neurotransmitter system involved in pain processing is 
the opioid system. Opioids play an important role in the descending modulation of 
pain and exogenously administered opioids seem to unfold their analgesic properties 
via descending pain-modulatory pathways. This was shown by early studies where 
the injection of naloxone, an opioid receptor antagonist, into the PAG of rabbits (Tsou 
& Jang, 1964), or the adjacent third ventricle of rats (Yeung & Rudy, 1980) 
counteracted the effect of systemic morphine administration. Coupling between ACC 
and PAG, which was associated with behavioral and neural placebo effects and RVM 
activation, was blocked by administration of naloxone (Eippert et al., 2009). In a µ-
opioid receptor tracer study using positron emission tomography (PET), µ-opioid 
receptor activation in response to painful stimulation was found in the ACC, PFC, 
insula, thalamus, hypothalamus, and the amygdala. This opioid receptor activation 
was further associated with reduced pain ratings (Zubieta et al., 2001). Hence the 
opioid system is not only involved in pain modulation on the level of the midbrain and 
brainstem, but also in cortical pain modulation. 
Other transmitter systems play important roles in descending inhibition as well. For 
example, there is evidence that different subregions of the PAG may be involved in 
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different forms of analgesia. Opioid analgesia appears to be mediated by the 
ventrolateral PAG while the dorsolateral portion of the PAG mediates non-opioid 
analgesia (Bandler & Shipley, 1994). This dorsolateral PAG pathway has been 
characterized as a cannabinoidergic pain control system in a study which showed 
that the microinjection of a cannabinoid receptor agonist into the dorsolateral PAG 
produced analgesia in rats, while the injection into the ventrolateral PAG had no 
significant effect (Martin, Patrick, Coffin, Tsou, & Walker, 1995). The modulatory role 
of the endocannabinoid system was confirmed by a study which showed that 
systemic administration of a cannabinoid receptor antagonist evoked significant 
thermal hyperalgesia (Richardson, Aanonsen, & Hargreaves, 1997) and analgesia 
produced by electrical stimulation in the PAG was accompanied by release of the 
endocannabinoid anandamide. This analgesic effect of electrical stimulation was 
reversed by administration of a cannabinoid receptor antagonist into the ventricles 
(Walker, Huang, Strangman, Tsou, & Sañudo-Peña, 1999). The endocannabinoid 
system also modulates cortical pain processing areas. In a human functional 
magnetic resonance imaging (fMRI) study, systemic administration of THC reduced 
functional connectivity between the thalamus and S2 and reduced effective 
connectivity to the hippocampus and the anterior insula (Walter et al., 2016). 
Endocannabinoid signaling depends on retrograde signaling, where the release of 
endocannabinoids from the post-synaptic cell modulates activity of the pre-synaptic 
neuron (Wilson & Nicoll, 2001). Therefore cannabinoid action is not independent of 
other neurotransmitter systems. For example, it could be shown that analgesia after 
systemic administration of a cannabinoid receptor agonist was neutralized by 
injection of an agonist of the GABA (γ-aminobutyric acid) receptor type A into the 
RVM (Meng, Manning, Martin, & Fields, 1998). Hyperalgesia induced by systemic 
administration of an endocannabinoid receptor antagonist was also blocked by the 
administration of two antagonists of the NMDA (N-methyl-D-aspartate) receptor 
(Richardson, Aanonsen, & Hargreaves, 1998), which represents an interaction 
between the endocannabinoid and the glutamatergic transmitter system in 
descending pain modulation. 
Overall, the facilitation of nociception is associated with activity in transmitter systems 
such as glutamate, histamine, cholecystokinin, melanocortin, and prostaglandins. 
The inhibition of nociception includes transmission involving GABA, glycine, 
vasopressin, oxytocin, adenosine, endogenous opioids, and endocannabinoids. A 
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comprehensive discussion of all the systems exceeds the scope of this introduction. 
For a review see Butler & Finn (2009) or Millan (2002). 
1.2.4 Stress-induced analgesia 
Lesion studies in rats have provided first insight into the neuronal representation of 
SIA and include data supporting the involvement of brain areas of the descending 
pain modulatory pathways. Lesions to the central nucleus of the amygdala were 
reported to impede SIA induced by 20 minutes of intermittent foot shock (Werka, 
1994). SIA induced by a cold water swim test was further suppressed by lesions in 
the hypothalamus (Truesdell & Bodnar, 1987) and lesions of the frontal cortex 
reduced SIA after repetitive short electrical foot shocks, but could not block SIA 
induced by repetitive 25 second long electrical stimulation (Meagher, Grau, & King, 
1989). It therefore seems likely that different types of stressors unfold their analgesic 
potential via different pathways.  
Other studies using suppression or enhancement of neurotransmission in specific 
brain areas have additionally shown the involvement of the PAG. Microinjection of an 
opioid receptor antagonist into the ventrolateral PAG of rat pups suppressed SIA 
induced by exposure to an unfamiliar adult male rat (Wiedenmayer & Barr, 2000). For 
the involvement of opioidergic neurotransmission in SIA, substantial evidence has 
been accumulated. Systemic administration of an opioid receptor antagonist 
suppressed the effects of a stressor on human NFR (Willer et al., 1981). In studies in 
rodents, naloxone-induced suppression of SIA was shown to be dose dependent 
(Bodnar, Kelly, Spiaggia, Ehrenberg, & Glusman, 1978) and to depend on opioid 
receptors that are located in the PAG as shown by microinjections of naloxone into 
the PAG instead of systemic administration (Miczek, Thompson, & Shuster, 1985). 
Whether the hypo-thalamic-pituitary-adrenal (HPA) axis, a system known to regulate 
neuroendocrine reactions to stress, is involved in SIA is still a topic of debate (Gaab 
et al., 2017). It was shown that SIA induced by cold water swim stress was 
diminished after hypophysectomy in rats (Bodnar, Glusman, Brutus, Spiaggia, & 
Kelly, 1979). On the other hand, SIA was successfully induced in hypophysectomized 
rats after transauricular electrical stimulation and was suppressed by naloxone 
administration. Therefore opioid-mediated SIA, induced by brief electrical shocks, 
seems to be independent of HPA axis functioning (Lewis, Cannon, Chudler, & 
Liebeskind, 1981). 
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Early studies implicate that the opioid involvement in SIA depends on the nature of 
the stressor. While a short and intermittent stressor produced opioid dependent SIA, 
SIA induced by continuous stress seems to depend on other neurotransmitter 
systems (Lewis et al., 1980). Non-opioid SIA may be mediated via cannabinoidergic 
pathways as is suggested by evidence showing that microinjection of a cannabinoid 
receptor antagonist into the basolateral amygdala attenuated SIA induced by 
continuous foot shock (Connell, Bolton, Olsen, Piomelli, & Hohmann, 2006) as well 
as the blockade of the cannabinoid receptor type 1 (CB1) in the PAG, whereas an 
opioid receptor antagonist injection into the PAG had no effect on this type of SIA 
(Hohmann et al., 2005). Other systems that seem to be involved in the mediation of 
opioid or non-opioid SIA include GABA (Lau & Vaughan, 2014), Serotonin (Yesilyurt 
et al., 2015), Oxytocin (Robinson et al., 2002) and Glutamate (Onodera et al., 2001). 
Human studies on the neurochemical mechanisms of descending inhibitory pathways 
in SIA are rare. One of those studies could show that the re-exposure to a stimulus 
which was previously paired with a stressor, induced a SIA response, which was 
attenuated by systemic administration of an opioid receptor antagonist (Flor, 
Birbaumer, Schulz, Grüsser, & Mucha, 2002). Salivary cortisol was not associated 
with the SIA effects in a study using a psychosocial stress paradigm, which suggests 
that the HPA axis does not seem to mediate this type of SIA (Gaab et al., 2017). 
There are also only few studies on the neuronal representation of SIA in higher 
cortical areas in humans. One of those studies showed that SIA effects were 
associated with activation in the ACC by using fMRI during painful stimulation before 
and after stress (Yilmaz et al., 2010). 
Despite of the growing evidence on the neuronal mechanisms of SIA there are still 
some gaps in the human literature: 1) It is unknown whether animal findings on the 
endocannabinoid mediation of SIA can be translated to the human brain. 2) The 
localization of opioid and cannabinoid action in mediating SIA has not been assessed 
in humans. 
1.2.5 Controllability 
There is increasing evidence that the pain modulatory effect of control over a painful 
stimulation is mediated by an activation of descending pathways via projections of 
the PFC. 
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In studies using fMRI in humans, uncontrollable compared to controllable painful 
stimulation was associated with higher activity in the ACC, insula, S2 and PAG 
(Salomons, Johnstone, Backonja, & Davidson, 2004; Salomons, Johnstone, 
Backonja, Shackman, & Davidson, 2007). On the other hand higher anticipatory 
activation of the ventrolateral PFC during controllable pain was correlated with 
stronger control-induced analgesia (Salomons et al., 2007). The functional 
connectivity of the PFC-PAG axis was related to control-induced analgesia in a safety 
signaling paradigm (Wiech et al., 2014) and pain facilitation during uncontrollable 
pain was associated with functional connectivity between insula and medial PFC, 
whereas pain inhibition was associated with functional connectivity between insula 
and dorsolateral PFC (Bräscher et al., 2016). Therefore PFC activity is not only 
involved in the activation of the descending inhibitory pain control system in the PAG 
via top-down processing, but also in descending facilitation during uncontrollable 
pain. By inhibition of the dorsolateral PFC using transcranial magnetic stimulation its 
inhibitory effects could be suppressed, which additionally confirms this pathway. 
Interestingly this effect was only found for the affective dimension of pain, but not the 
sensory pain component (Borckardt et al., 2011). 
PFC activation was further shown to be associated with the coping behavior of the 
participants in a study on exerted control. Control-related analgesia was not only 
related to PFC activation, but this activation was also correlated with the subjects’ 
personal belief that pain can be controlled by their own action (internal locus of 
control). External locus of control on the other hand was negatively associated with 
this top-down modulation of control-related analgesia (Wiech et al., 2006). 
The frontal modulation of control-induced analgesia was divided into modulation by 
perceived controllability and modulation by exerted controllability: The OFC and 
mediofrontal cortex selectively responded to perceived control, whereas the PFC 
responded to exerted control (Mohr et al., 2012). 
Despite this fair amount of insight into neural mechanisms of control-induced 
analgesia some questions remain unanswered: (1) Studies on neurochemical 
correlates of control-induced analgesia are lacking. (2) The effect of control-induced 
analgesia on different dimensions of the painful experience remains to be elucidated 
because of the heterogeneity of the studies in respect to their outcome measures. 
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1.3 Dimensions of pain and suffering 
A better understanding of the mechanisms that drive pain and pain relief is as 
important as a clear understanding of the outcome measures that we use to assess 
pain (Ballantyne & Sullivan, 2015). Fifty years ago pain has been described as a 
multidimensional phenomenon in terms of three dimensions of pain processing: the 
“sensory-discriminative” dimension, which encompasses intensity as well as spatial 
and temporal information of the nociceptive input, the “motivational-affective” 
dimension, which encompasses the aversive drive of the nociceptive input and the 
“cognitive-evaluative” dimension that puts the nociceptive input in relation to past 
experiences or control actions (Melzack & Casey, 1968). 
In the last decades the “sensory-discriminative” and the “motivational-affective” 
dimension, mostly just labelled as pain intensity and pain unpleasantness have 
received most attention in research. Although pain intensity and unpleasantness are 
highly correlated with each other (Chapman et al., 2001), hypnotic suggestions have 
been used to selectively alter pain affect without changing the perceived intensity in 
response to noxious stimuli (Rainville, Duncan, Price, Carrier, & Bushnell, 1997) and 
also to alter pain intensity with little effect on pain unpleasantness (Rainville, Carrier, 
Hofbauer, Bushnell, & Duncan, 1999). Furthermore, pain intensity and pain 
unpleasantness have been related to differential facial response patterns (Kunz, 
Lautenbacher, LeBlanc, & Rainville, 2012). 
Further evidence for separate pain dimensions stems from the case of a stroke 
patient with lesions in primary and secondary somatosensory cortex, who showed 
unilateral loss of the sensory-discriminative pain component with a preserved 
motivational-affective pain component (Ploner, Freund, & Schnitzler, 1999). This 
effect of lesions in the somatosensory cortex was confirmed in rats with lesions in the 
hind limb area compared to rats which underwent a sham procedure. The lesioned 
rats showed a loss of the sensory pain component, indicated by higher paw 
withdrawal thresholds, but a preserved motivational-affective pain component, as 
indicated by preserved avoidance of an area that was associated with noxious 
stimulation (Uhelski, Davis, & Fuchs, 2012). 
Later theories extended the pain intensity and pain unpleasantness dimensions by 
subdividing them into three dimensions. Fields (1999) proposed the term algosity for 
a sensory stimulus quality that uniquely identifies pain in contrast to other unpleasant 
stimuli such as itch, the term primary unpleasantness to describe the unpleasantness 
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of the painful stimulus, which is directly related to its sensory properties and the term 
secondary unpleasantness to describe an experience that reflects a higher level 
process which is largely determined by memories and contextual features. An 
analogous concept was introduced by Price (2000): Next to the nociceptive 
sensations evoked by a noxious stimulus, he distinguished between the immediate 
pain unpleasantness, which encompasses feelings that pertain to the present or 
short-term future and the secondary pain affect, which includes feelings directed 
towards long-term implications of having pain, such as suffering. 
This dimension of suffering that was newly introduced in both the theoretical 
concepts of Fields (1999) and Price (2000) has been underestimated in its clinical 
importance and often neglected in research on chronic pain (Ballantyne & Sullivan, 
2015). This is especially surprising, given that suffering is the most important factor 
that drives patients to seek medical attention (Carnevale, 2009). Suffering is a 
personal experience and has been described as a pronounced state of distress, 
which threatens the physical or psychological integrity of a person through 
helplessness, loss of control, and concerns about the future (Cassel, 1982). 
With experimental pain paradigms in healthy volunteers Bustan et al. (2015) and 
Brunner et al. (2017) have shown that suffering can be part of the painful experience 
that is influenced by enduring characteristics of the person, such as fear of pain and 
increased private self-consciousness (Brunner et al., 2017). It is unclear from the 
empirical perspective which other factors affect the experience of pain-related 
suffering and what might rather affect the aspect of pain intensity or (primary) pain 
unpleasantness. 
1.4 Aims and hypotheses 
The aim of this dissertation was to gain further insight into pain inhibitory factors such 
as stress and controllability. 
In study 1 healthy volunteers (n=19) were tested on 3 separate days. In a 
randomized, double-blinded cross-over design the activation of descending inhibitory 
pathways by stress was tested after systemic administration of CBD, THC and 
placebo. Activation of descending pain inhibition was assessed with ratings of pain 
intensity and pain unpleasantness and the BOLD response in the fMRI. The first 
hypothesis addressed the role of endocannabinoid signaling in SIA in humans: 
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1.1. The administration of THC will enhance the reduction of pain intensity and 
pain unpleasantness ratings after a mental stressor. 
1.2. The administration of CBD will suppress the reduction of pain intensity and 
pain unpleasantness ratings after a mental stressor. 
 
The second hypothesis addresses the modulation of underlying brain circuits 
involved in cannabinoid-mediated SIA: 
 
2.1. SIA after administration of THC is associated with increased BOLD 
responses in the amygdala, PAG and ACC. 
2.2. SIA after administration of CBD is associated with decreased BOLD 
responses in the amygdala, PAG and ACC. 
 
In study 2 healthy volunteers (n=26) were tested to assess pain inhibition by 
manipulation of controllability. Pain inhibition was measured with ratings of pain 
intensity, pain unpleasantness and pain-related suffering, the electromyogram of the 
corrugator muscle, skin conductance responses and heart rate. 
 
3.1. Controllable painful stimulation is rated with lower pain intensity, pain 
unpleasantness and pain-related suffering, when compared to uncontrollable 
painful stimulation. 
3.2. Differences between controllable and uncontrollable painful stimulation in 
the rating of pain-related suffering will be higher than for pain intensity or pain 
unpleasantness. 
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2 ORIGINAL CONTRIBUTIONS 
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2.1 The influence of tetrahydrocannabidiol and cannabidiol on pain perception and 
endogenous pain control1 
  
                                                 
1Löffler, M., Kamping, S., Grimm, O., Andoh, J., Rohleder, C., Leweke, M., Flor, H. 
(2018). The influence of tetrahydrocannabinol and cannabidiol on pain 
perception and endogenous pain control. Article submitted for publication. 
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Abstract  
The role of the endocannabinoid system in pain processing is increasingly gaining 
attention. Evidence for its involvement in endogenous pain control mechanisms 
mainly derives from animal research. So far, little is known about the effects of 
exogenously administered cannabinoids on endogenous pain inhibition. 
We employed functional magnetic resonance imaging (fMRI) during stress-induced 
analgesia (SIA) in 19 healthy humans and examined the influence of the 
administration of 10mg Tetrahydrocannabinol (THC) or 600mg Cannabidiol (CBD) 
versus placebo in a within-subjects design. Stress was induced by a cognitively 
demanding task with increasing noise levels. Electrical perception thresholds, pain 
thresholds, pain tolerance and perceived pain in response to repetitive electrical 
painful stimulation were assessed before and after stress exposure. We expected 
that THC, as an up-regulator of endocannabinoid signaling, would enhance SIA, 
while CBD, which interferes with cannabinoid signaling, should reduce SIA. 
We found that THC administration was associated with a disruption of within-session 
habituation to the painful stimulus without an enhancement of SIA. CBD neither 
affected habituation nor SIA. On the neuronal level, we found a modulation of frontal 
processing of pain by THC in line with assumptions about cannabinoid-mediated pain 
suppression. 
Our results suggest that systemic administration of cannabinoids might interfere with 
some aspects of the endogenous control of pain. Possible mechanisms of pain 
suppression are discussed. 
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Introduction  
Analgesic properties of cannabinoids have been shown in a variety of chronic pain 
patient populations [45; 46] and they are commonly applied for pain relief [69]. On the 
neuronal and neurochemical level a number of studies support the role of the 
endocannabinoid system in the central processing of pain. CB1 receptors are 
expressed in a number of brain regions involved in pain control [29; 65], and thalamic 
CB1 [57] as well as spinal CB1 and CB2 receptors were upregulated in rat models of 
chronic neuropathic pain [43; 77]. Microinjection of a CB1 receptor agonist showed 
antinociceptive CB1 action in the amygdala, thalamus, superior colliculus and the 
noradrenergic A5 region [50]. 
In human studies THC and CBD are frequently used drugs to modulate activity of the 
endocannabinoid system. These exogenously administered cannabinoids target the 
endocannaboid system with its cannabinoid receptors type 1 (CB1) and type 2 (CB2), 
their ligands 2-Arachidonoylglycerol (2-AG) and Anandamide and the anandamide 
degrading enzyme fatty-acid amide hydrolase (FAAH) and the 2-AG-degrading 
enzyme monoacylglycerol lipase (MGL). While THC acts as a cannabinoid receptor 
agonist, and unfolds most of its pharmacological effects selectively at the CB1 and 
CB2 receptors, CBD acts as a partial antagonist at the CB1 receptor [21], but other 
modes of CBD action may include the inactivation of FAAH, modulation of 
endocannabinoid reuptake into the cell or interactions with the transient receptor 
potential channels of vanilloid type-1 and the serotonin receptor 5-HT1A, but remain 
unclear [47]. Brain imaging has revealed that THC and CBD have opposite effects on 
activation in the amygdala, anterior cingulate cortex, insular cortex, medial and lateral 
prefrontal cortex [11], areas also involved in pain processing [23]. 
However, the exact mechanisms of cannabinoid pain modulation are still unclear. On 
the one hand studies on the analgesic properties of exogenous administered CB1 
agonists or smoked marijuana found analgesic effects [18; 28]. Other studies found 
no pain modulation [51] or even hyperalgesic effects [8; 51; 68]. A possible 
mechanism of CB-mediated analgesia is the activation of the descending pain 
pathway. This pathway was shown to be activated by stress and mediated by eCB 
signaling [16; 19], however, most of the available data were assessed in animals. 
These animal studies targeted different areas of the descending inhibitory pain 
pathway. Administration of rimonabant, a CB1-selective inverse agonist, into the 
dorsolateral PAG attenuated fear-conditioned analgesia, which was associated with 
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increased levels of anandamide in the dorsolateral PAG [52]. Inhibiting the 
degradation of the endogenous cannabinoids anandamide or 2-AG in the PAG, 
increased the effects of non-opioid stress-induced analgesia (SIA) in rats [31]. 
Injection of rimonabant into the basolateral nucleus of the amygdala inhibited SIA in 
rats [17]. Additionally, SIA in mice was prevented by systemic administration as well 
as local injection of a CB1 receptor agonist into the PAG [40]. Evidence that CB1 
knockout mice do not show antinociception after stress exposure in a forced swim 
test [66] further supports the role of the endocannabinoid system in endogenous pain 
inhibition via the descending inhibitory pain pathway. 
In the present fMRI experiment we investigated the role of the endocannabinoid 
system in human endogenous pain inhibition. We used blocks of repetitive painful 
electrical stimulation before and after a cognitive stressor to test the effects of THC 
and CBD on SIA. We hypothesized that THC would enhance, whereas CBD would 
disrupt SIA compared to a placebo condition. This modulation of the SIA effect was 
expected to be associated with increased BOLD response in the amygdala, PAG and 
ACC after administration of THC, but reduced activity in the same areas after the 
administration of CBD. 
 
Methods 
Subjects 
Twenty healthy male volunteers participated in the study. One subject withdrew from 
participation because of vertigo after substance administration on visit 2. The final 
sample consisted of 19 male, right-handed volunteers between 19 and 35 years of 
age (mean age: 24.74, standard deviation (SD) = 4.617; mean body weight: 76.263 
kg, SD=9.182, range 63-99 kg). The study was approved by the Ethics Committee of 
the Medical Faculty Mannheim, University of Heidelberg, Germany and the Federal 
Institute for Drugs and Medical Devices (BfArM). Written informed consent was 
obtained from each subject prior to the study and on each examination day (four 
times in total). Exclusion criteria were cardiovascular or neurological disorders, brain 
injury, acute or chronic pain, pain medication, lifetime and current substance abuse 
or dependence and any mental disorders. The subjects were examined by a 
psychologist using the German version of the Structured Clinical Interview for DSM 
IV Axis I disorders [72] to exclude subjects with a mental disorder. Additionally, all 
participants were examined by a registered psychiatrist and blood sampling was 
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performed for medical chemistry and drug screening. None of the participants 
reported any physical or mental disorders and their drug tests were negative. Two 
participants were smokers (one subject with two cigarettes a day, the other with 14 
cigarettes a day), the others were non-smokers. 
 
Experimental procedure 
In a randomized, double-blind, placebo-controlled study the acute effects of orally 
administered THC (10 mg), CBD (600 mg) and placebo (vehicle) on SIA were 
compared. Each participant took part in all arms of the study. Blinding was performed 
at the University Pharmacy of the University of Heidelberg. Unblinding took place 
after all participants completed the study. The experiment was spread over four 
separate days. The first day was a diagnostic session where participants underwent 
a psychological and medical examination including drug screening. Testing sessions 
were conducted on days two to four, all separated by at least one week (>3 times 
elimination half-life of THC: [20] and CBD: [48]). The same tests were performed in 
each session (see Figure 1 & Table 1). 
 
Monitoring of pharmacokinetics and mental state of the participants 
To improve the interindividual comparability of absorption rates and 
pharmacodynamics, the participants received a standard meal on arrival. 
Cannabinoids have been shown to modulate mood, anxiety [49] and dissociative 
symptoms [54]. These symptoms were therefore assessed during the experiment. To 
monitor pharmacokinetics and mental state, blood samples were taken and the 
participants completed the state version of the German version of the Spielberger 
State-Trait Anxiety Inventory (STAI-S) [39], the German version of the Positive and 
Negative Affect Scale (PANAS) [35], self-assessment manikin (SAM) ratings of 
valence and arousal [13] and a short version of the Dissociation-Tension-Scale acute 
(DSS-4) [59; 60]. Blood samples and questionnaire measurements were taken three 
times: immediately before substance administration (t0), 1 hour after substance 
administration (t1) and at approximately three hours after substance administration 
(t2). 
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Table 1: Time line of the experimental procedure for each condition (placebo, THC and CBD) for blood samples (t0, t1, t2), drug 
administration (drug), threshold determinations (thresh pre, thresh post) and painful stimulation blocks (Pain stim pre, pain stim post) 
before and after the stress induction (stress). All values refer to time since substance administration in minutes.1 
Timing 
t0 drug t1 
Thresh 
pre 
Pain 
stim pre 
stress 
Pain 
stim 
post 
Thresh 
post 
t2 
M±SD M M±SD M±SD M±SD M±SD M±SD M±SD M±SD 
Placebo -5±3 0 62±1 74±4 99±4 113±4 134±8 140±5 199±9 
THC -5±3 0 61±3 77±9 102±9 115±9 136±9 143±10 205±14 
CBD -6±3 0 62±3 77±10 103±9 117±9 138±10 145±10 209±14 
1 M: mean, SD: standard deviation 
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Figure 1: Structure of the experiment from left to right. At t0 baseline blood levels of THC and CBD were determined. At t1 blood 
levels were determined at approximately 1 hour after drug administration (see Table 1 for timing details). At t2 blood levels  were 
determined at the end of the experiment. Pain thresholds (orange) and painful stimulation (red: 10 stimulation blocks with durati on 
11.76 sec each, stimulus duration 2ms, 105 stimuli, inter stimulus interval = 112 ms, which were always followed by off block s of 11.76 
seconds duration) were implemented before (PRE) and after (POST) stress induction with a cognitive demanding task. Blood pres sure 
and heart rate was recorded at baseline (pre-baseline), during the stressor (stress) and after the stressor (post-baseline). Functional 
magnetic resonance (fMRI) imaging was implemented during painful stimulation. For post-acquisition correction for physiological noise 
cardiac and respiration data were acquired during fMRI scanning. 
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Blood samples were centrifuged at 4°C for 5 min at 4000 rpm. Supernatant was 
transferred into glass vials (Hycultec GmbH, Beutelsbach, Germany) and 
immediately frozen and stored at –80°C until liquid-liquid extraction of THC and CBD. 
During the extraction process, deuterated standards of THC and CBD were added to 
the serum aliquots, allowing for quantification of cannabinoid blood levels by isotope-
dilution LC-MS/MS. The LC-MS/MS system comprised an Agilent 1200 HPLC system 
(Agilent Technologies® Waldbronn, Germany) coupled to an API 5000 triple 
quadrupole mass spectrometer (AB Sciex® Darmstadt, Germany). Samples were 
injected into a Synergi Hydro-RP C18 column (150 x 2 mm, 4 µm, Phenomenex® 
Aschaffenburg, Gemany) and eluted using a methanol/water gradient with 0.1 % 
formic acid at a flow rate of 0.5 mL/min. THC and CBD were quantified by tandem 
electrospray mass spectrometry in positive ion mode (ES+). Product ions were 
monitored in multiple reaction monitoring (MRM) mode.  
 
Figure 2: Blood concentrations of THC and CBD. Black lines: Placebo condition; 
Grey lines: THC condition; Light grey lines: CBD condition. (a) THC blood 
concentration is depicted in picomoles per milliliter (pmol/ml) for each condition 
(Placebo, THC and CBD) and each time point (t0: baseline blood levels, t1: blood 
levels at approximately 1 hour after drug administration, t2: blood levels at the end of 
the experiment). (b) CBD blood concentration is depicted in picomoles per milliliter 
(pmol/ml) for each condition (Placebo, THC and CBD) and each time point (t0: 
baseline blood levels, t1: blood levels at approximately 1 hour after drug 
administration, t2: blood levels at the end of the experiment). 
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Threshold determination 
After substance administration, a pair of subcutaneous needle electrodes (20 mm 
long, 0.35-mm uninsulated tip, 2-mm² stimulation area, model: 9013R0272, 28G, 
Alpine Biomed ApS, Skoviunde, Denmark) was placed subcutaneously at the left 
lower back, 2 cm lateral to the spine, between L1 and L3 (1 mm needle separation) 
for electrical stimulation. Electrical stimuli were applied using a constant current 
stimulator (model DS7A; Digitimer, Hertfordshire, England). The experiment was 
performed using Presentation® software (Version 14.0, http://www.neurobs.com/). 
Perception threshold, pain perception threshold and pain tolerance were assessed 
before and after the stressor. The participants received ascending electrical 
stimulation trains (Stimulation train: 8 stimuli of 2ms, inter stimulus interval = 
112msec, inter train interval = 2sec) via the subcutaneous needle electrodes and 
were instructed to press a button when they could feel the stimulus for the first time 
(perception threshold), when the stimulus was painful for the first time (pain 
threshold) and when they could not tolerate a higher stimulus intensity (pain 
tolerance). Each measure was determined four times.  
After the first threshold determination, the stimulation intensity was calibrated at a 
perceived pain intensity of 50 percent on a VAS (endpoints “no pain” and “worst pain 
imaginable”) that was converted to a 0 to 100% scale. The first threshold assessment 
was discarded and 50 percent of the difference between pain threshold and pain 
tolerance were added to the pain threshold, to calculate a preliminary stimulation 
intensity. In test trials (duration 12.544 seconds each, stimulus duration 2ms, 112 
stimuli, inter stimulus interval 112msec) the perceived pain intensity was assessed 
using a VAS. The stimulation intensity was adapted between the test trials to reach a 
pain intensity rating of 50 out of 100 points, or to reach a rating closest possible to 
50. The resulting stimulation intensity of each subject was used for all further 
procedures. 
 
Pain stimulation before and after stress induction 
To examine changes in pain perception and BOLD response to painful stimuli, the 
participants received trains of electrical stimulation before and after the stressor. 
They were instructed to look at a fixation cross and received 10 stimulation blocks 
(duration 11.76 sec each, stimulus duration 2ms, 105 stimuli, inter stimulus interval = 
112 ms), which were always followed by off blocks of 11.76 seconds duration. The 
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perceived levels of pain intensity and pain unpleasantness were assessed after the 
first (‘Early’) and the last (‘Late’) stimulation block using visual analogue scales (VAS) 
ranging from “no pain” to “worst pain imaginable”, and “not unpleasant” to “extremely 
unpleasant”. 
 
Stress induction 
The stressor used in this study was mental arithmetic combined with white noise. The 
mental arithmetic tasks were similar to those from the Konzentrations- und 
Leistungstest (Concentration and Performance Test: [24; 44]) and were presented by 
a female voice via earphones. Such mental arithmetic tasks have previously shown 
to be effective in the induction of stress [26; 76]. Each task consisted of a series of 
two sets of three numbers (e.g. 5,9,4 and 3,8,11) that had to be added or subtracted. 
If the sum of the second set was smaller than the sum of the first set, the second 
result had to be subtracted, if the sum of the first set was smaller than that of the 
second set, the first result had to be added (i.e. 18+22 in this example). In our 
experiment an additional third arithmetic operation had to be executed after 
subtraction or summation (e.g. 40*2) and the subject had to verbally report the final 
result (i.e. 80 in this example). Each task had to be solved within 30s. In total 
subjects had to solve 30 tasks on each experimental day, resulting in a duration of 
the stressor of 15 minutes. 
To account for individual cognitive performance, five parallel versions of the mental 
arithmetic task with varying difficulty (based on the arithmetic operations) were 
prepared. During the diagnostic session on day one, the individual difficulty level was 
determined for each participant. For that purpose, 5 tasks of the lowest level of 
difficulty were presented. If the participant solved at least four of those, the next level 
was presented. If the participant solved at least four tasks at the second level again, 
the next level was presented. This was continued until the participant made more 
than one error within a level or the highest level was reached. One level above the 
resulting difficulty level was then used on the second day of the experiment for stress 
induction. The difficulty had to be increased for 5 participants and decreased for one 
participant between the sessions. The level was considered as too easy if a 
participant solved more than 20 and too difficult if a participant solved less than 5 
tasks. On each day the same set of tasks was used, but presented in a different 
pseudorandomized order. In order to increase the stressfulness of the task white 
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noise was presented continuously and increased from 65 to 80 dB from the first to 
the last arithmetic calculation. 
 
Heart rate, blood pressure, and ratings of the stressor 
To assess physiological effects of the stressor, blood pressure was measured with 
the MR compatible Criticare 506N vital signs monitor (Criticare Systems Inc., 
Waukesha, USA), using a sampling rate of one per minute. Heart rate was assessed 
with the built-in pulsoxymeter of the MR, using a sampling rate of 50Hz. Heart rate 
and blood pressure were measured during a 5 minute resting interval immediately 
before the stress phase, throughout the 15 minutes of the stress phase and during a 
5 minute resting phase at the end of the experiment. 
The participants were asked to verbally rate how stressed (0 = not stressed – 100 = 
extremely stressed) and how relaxed (0 = not relaxed – 100 = extremely relaxed) 
they were immediately before the stress phase, immediately after the stress phase 
(indicating how stressed/relaxed they were during the stress phase), and immediately 
after the last heart rate measurement. 
 
Magnetic resonance imaging 
Magnetic resonance images were obtained on a 3-T TRIO Siemens (Erlangen, 
Germany) scanner (TR = 1.96 seconds, TE = 30 ms, flip angle 76°, slice thickness 3 
mm, 36 slices, field of view 220 mm, 3.4 X 3.4 X 3.0 mm voxel size) using an echo 
planar (EPI) T2* sensitive sequence. Parallel acceleration technique (iPAT) with 
generalized auto-calibrating partially parallel acquisition (GRAPPA) reconstruction 
was used with an acceleration factor of 2. Field map images (TR = 468 ms, TE1 = 
4.92 ms, TE2 = 7.38 ms, flip angle 60°, slice thickness 3 mm, 36 slices, field of view 
220 mm, 3.4 X 3.4 X 3.0 mm voxel size) were obtained for post-acquisition correction 
of gradient field effects. Cardiac and respiration data were acquired with built-in 
pulsoxymeter and respiration belt for post-acquisition correction for physiological 
noise. Additionally, a high-resolution magnetization prepared rapid gradient (3D 
MPRAGE) (slice thickness 1 mm, TR = 2.3 seconds, TE = 3.03 msec, flip angle 9°, 1 
X 1 X 1 mm voxel size) was obtained for each subject on each session. 
 
Statistical analysis 
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The data were analyzed using R software [63]. Linear mixed effects models were 
employed for the analysis of ratings and thresholds. Mixed models were implemented 
using lme4 in R [7] and lmerTest [37] to provide F statistics for fixed effects. The 
participants' intercepts were entered into the models as subject-level random effects, 
the estimation method was restricted maximum likelihood (REML), and the 
covariance matrix was unstructured. All post-hoc tests were corrected for multiple 
comparisons using Bonferroni corrections.  
Stress ratings, blood pressure and heart rate were analyzed using the within-subject 
factors ‘drug’ (THC, placebo, CBD) and ‘stress’ (‘pre baseline’, ‘stress’, ‘post 
baseline’). Pain intensity ratings and pain unpleasantness ratings were analyzed 
using the within-subject factors ‘drug’ (THC, placebo, CBD), ‘time’ (early, late) and 
‘stress’ (‘pre’, ‘post’). Perception threshold, pain threshold and pain tolerance were 
analyzed using the within-subject factors ‘drug’ (THC, placebo, CBD) and ‘stress’ 
(‘pre’, ‘post’). T-Tests were used to compare initial perception and pain thresholds 
and pain tolerance. 
 
fMRI analysis 
Functional MRI data processing was carried out using FEAT (FMRI Expert Analysis 
Tool) Version (5.00), part of FSL (FMRIB's Software Library, 
http://www.fmrib.ox.ac.uk/fsl). At the first level (within-subjects), preprocessing 
involved several stages. The first three EPI volumes were deleted to eliminate tissue 
relaxation artifacts. Motion was corrected using MCFLIRT (motion correction based 
on FMRIB's Linear Image Registration Tool: [32]), and the resulting six motion-
correction parameters were used as regressors in the design matrix. We included 
nuisance regressors for time points corresponding to motion outliers using the FSL 
motion outliers program (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLMotionOutliers), which 
defined outlier time points using the upper threshold for creating box plots or the 75th 
percentile plus 1.5 times the interquartile range. Non-brain structures were removed 
using BET (Brain Extraction Tool: [58]). The data were spatially smoothed using a 5-
mm Gaussian kernel of full-width at half maximum. Each dataset was normalized by 
a single scaling factor (“grand mean scaling”), whereby each volume in a 4D dataset 
is normalized by the same value, to allow for cross-subject statistics to be valid. High-
pass temporal filtering with a 100-s cut-off was used to remove low-frequency drifts. 
The resulting denoised time series data were analyzed using a general linear model 
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(GLM) approach. Registration to MNI152 standard space was carried out using 
FNIRT nonlinear registration [3; 4]. Painful stimulation trials were modeled as three 
separate factors of interest (Stimulation Block 1 to 5: “early stimulation”, stimulation 
block 6 to 10: “late stimulation” and “rating”), and the estimated motion parameters, 
motion outliers and physiological noise (cardiac and respiration data, preprocessed 
using physiological noise modeling (PNM), [14]) for each subject were included as 
nuisance regressors to reduce spurious activations because of cardiac cycle, thereby 
increasing statistical sensitivity. Areas of significant fMRI responses were determined 
using clusters identified by a z > 2.3 threshold and a corrected cluster threshold of 
p = 0.05 assuming a Gaussian random field for the Z-statistics [74]. 
 
Results  
Effects of stressor and drugs on perceived stress and autonomic stress responses  
The analysis of perceived stress ratings across all substances showed a significant 
effect of stress (F(2,144)=176.382; p<.001) with higher stress levels during the 
stressor compared to the pre (t(18)=10.42, p<.001) and post baseline (t(18)=10.46, 
p<.001). There was no significant drug effect on perceived stress (F(2,144)=0.51; 
p=.60) and no significant interaction of drug x stress for perceived stress 
(F(4,144)=0.34; p=.85). Participants experienced high levels of stress in all 
conditions, see Figure 3. 
Blood pressure (systolic: F(2,144)=19.07; p<.001; diastolic: F(2,144)=39.88; p<.001) 
was significantly increased during the stress phase, with higher blood pressure 
during the stressor compared to the pre (systolic: t(18)=5.90, p<.001; diastolic: 
t(18)=7.16, p<.001) and post baseline (systolic: t(18)=3.94, p<.001; diastolic: 
t(18)=3.83, p=.001). At the end of the experiment blood pressure had not fully 
returned to baseline but remained at a higher level than during the pre baseline 
(systolic: t(18)=5.85, p<.001; diastolic: t(18)=5.58, p<.001). Additionally, we found a 
significant main drug effect on diastolic blood pressure (F(2,144)=4.46; p=.013), 
however, post-hoc-tests between the drugs did not yield significant differences (all 
t(18)<1.91, p>.18). 
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Figure 3: Perceived stress and psychophysiological changes induced by the stressor. Black lines: Placebo condition (PLA); Grey 
lines: THC condition; Light grey lines: CBD condition. All graphs show data before (pre), during (stress) and after the stres sor (post). 
Error bars display the standard error of the mean. Asterisks indicate significant post-hoc tests at ***p<.001. (a) Shows stress ratings on 
a visual analogue scale (VAS) ranging from “not stressed” to “extremely stressed”, transformed to values ranging from 0 to 100, (b) 
displays systolic and diastolic blood pressure, (c) shows heart rate in beats per minute (bpm). 
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The analysis of heart rate across all substances showed a significant effect of stress 
(F(2,143.02)=54.21; p<.001) with higher heart rate during the stressor than during the 
pre (t(18)=5.35, p<.001) or post baseline (t(18)=4.87, p<.001). At the end of the 
experiment heart rate had not fully returned to baseline, but remained at a higher 
level than during the pre baseline (t(18)=3.17, p=.005). Additionally, we found a 
significant main drug effect on heart rate (F(2,143.02)= 6.00; p=.003), with higher 
heart rate in the THC compared to the CBD condition (t(18)=2.82, p=.03). The heart 
rate in the THC condition (t(18)=1.53, p=.14) and the CBD condition (t(18)=1.83, 
p=.12) did not differ significantly from placebo. There was no significant interaction of 
drug x stress (F(4,143.02)=1.08; p=.37). 
 
Blood concentration levels of THC and CBD 
Blood concentrations of THC (t0: 0±0 pmol/ml; t1: 1.11±4.82 pmol/ml; t2: 
16.84±14.12 pmol/ml) and CBD (t0: 0±0 pmol/ml; t1: 6.47±20.32 pmol/ml; t2: 
537.56±340.06 pmol/ml) showed a clear peak at t2 (see Figure 2). 
 
Effects of THC and CBD on pain perception and endogenous pain inhibition  
The analysis of thresholds across all substances showed a significant effect of stress 
with higher perception thresholds (F(1,90)=11.49; p=.001), higher pain thresholds 
(F(1,89.99)=12.24; p<.001) and higher pain tolerance (F(1,84.995)=16.4; p<.001) 
after the stressor. There was a significant drug effect on perception threshold 
(F(2,90)=3.73; p=.03), post-hoc-tests between the drugs, however, did not yield 
significant differences (all t(18)<1.91, p>.21), and no significant drug effect on pain 
threshold (F(2,89.99)=1.72; p=.19) or pain tolerance (F(2,84.995)=1.02 p=.36) and 
no significant interaction of drug x stress for perception threshold (F(2,90)=0.40; 
p=.67), pain threshold (F(2,89.99)=0.04; p=.96) or pain tolerance (F(2,84.995)=0.15; 
p=.86). This indicates reduced sensitivity to painful and non-painful stimuli after 
exposure to stress, which was, however, not modulated by THC or CBD (see Figure 
4c). 
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Figure 4: Pain ratings and thresholds for each condition and each time point. Black 
lines: Placebo condition (PLA); Grey lines: THC condition; Light grey lines: CBD 
condition. (a) The x-axis depicts the time during the experiment in relation to the 
stressor (1= Early|Pre, 2=Late|Pre, 3=Early|Post, 4=Late|Post). The y-axis depicts 
pain intensity ratings on a visual analogue scale (VAS) ranging from “no pain” to 
“worst pain imaginable”, which was transformed to values from 0 to 100. Error bars 
show the standard error of the mean. Asterisks indicate color-coded significant post-
hoc tests at *p<.05, **p<.01 and ***p<.001. (b) The x-axis depicts the time during the 
experiment in relation to the stressor (1= Early|Pre, 2=Late|Pre, 3=Early|Post, 
4=Late|Post). The y-axis shows pain unpleasantness ratings on a visual analogue 
scale (VAS) ranging from “not unpleasant” to “extremely unpleasant”, which was 
transformed to values ranging from 0 to 100. Error bars show the standard error of 
the mean. Asterisks indicate color-coded significant post-hoc tests at *p<.05, **p<.01 
and ***p<.001. (c) The x-axis depicts the time before (Pre) and after (Post) the 
stressor. The y-axis depicts electrical currents of pain tolerance, pain threshold and 
perception threshold (from top to bottom) in milliampere (mA). Error bars show the 
standard error of the mean. Asterisks indicate significant main effect of time at 
***p<.001. Black lines: Placebo condition; Grey lines: THC condition; Light grey lines: 
CBD condition. 
 
The analysis of pain intensity ratings (see Figure 4a) across all substances showed a 
significant effect of drug (F(2,197.04)=4.49; p=.012). Pain intensity ratings decreased 
from early to late stimulation blocks (F(197.04=42.47; p<.001) and from the pre to the 
post stressor phase (F(1,197.04)=6.59; p=.011). The same effects of drug 
(F(2,197.08)=4.42; p=.013), time (F(1,197.08)=23.98; p<.001) and stress 
(F(1,197.08)=12.80; p<.001) were found for the pain unpleasantness ratings (see 
Figure 4b). Post-hoc tests showed that pain unpleasantness ratings were significantly 
higher in the THC condition than in the CBD condition (t(18)=2.64; p=.05), but no 
significant differences were found when THC (t(18)=.88; p=.39) or CBD (t(18)=1.91; 
p=.11) were compared to placebo. For pain intensity ratings, post-hoc tests showed 
no significant differences between the drugs (all t(18)<1.95; p>.19). 
A significant interaction effect for time x drug was found in pain unpleasantness 
ratings (F(2, 197.08)=3.16; p=.04), but not in pain intensity ratings (F(2, 
197.04)=2.79; p=.06). There were no other significant main or interaction effects for 
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pain ratings (all F<1.90; p>.14). Separate analyses comparing THC with placebo and 
CBD with placebo showed that the drug x time interaction effect was driven by the 
comparison between THC and placebo. The interaction drug x time was significant 
for pain intensity (F(1,125.1)=4.98; p=.027) and pain unpleasantness ratings 
(F(1,126)=5.46; p=.02), when THC was compared to placebo. Participants reported 
strong decreases of pain intensity and unpleasantness during the stimulation in the 
placebo condition, those decreases were less pronounced under the influence of 
THC. When CBD was compared to placebo, this interaction effect showed a trend 
towards significance for pain intensity ratings (F(1,125.04)=3.74; p=.06), indicating 
stronger decreases of pain intensity in the placebo condition than in the CBD 
condition, but was insignificant for pain unpleasantness ratings (F(1,125.15)=0.79; 
p=.38). 
 
Effects of drugs on anxiety, mood and dissociative symptoms 
The analysis of the DSS-4 across all substances showed a significant effect of time 
(F(2,143.97)=4.95; p=.008) and a significant interaction of time x drug 
(F(4,143.97)=3.11; p=.02), but no main effect of drug (F(2,143.97)=2.27; p=.11). 
These effects reflect two subjects who reported dissociative symptoms or tension on 
the DSS-4 at the end of the THC condition (6.5 and 3 points on a 0 to 9 scale). All 
other subjects reported little or no dissociative symptoms (<1.5 points on the DSS-4). 
The analysis of the PANAS revealed that positive affect decreased over time 
(F(2,144)=25.03; p<.001). Positive affect was highest at the beginning of the 
experiment and decreased 1 hour after drug administration (t(18)=3.63; p=.001) and 
decreased again until the end of the experiment (t(18)=3.83; p=.001). There was no 
significant drug effect (F(2,144)=0.008; p=.99) or drug x time interaction effect 
(F(4,144)=0.08; p=.99) on positive affect. Negative affect was not affected by drug or 
time effects (all F<2.39; p>.09). 
The analysis of the anxiety ratings of the STAI-S revealed no significant drug or time 
effects (all F< 2.79; p>.06). Overall, this suggests that participants where in a less 
positive mood towards the end of the experiment, which was, however, not affected 
by drug administration. 
 
fMRI recordings 
Pre- and post-stress phase 
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Independent of the administered drug, the BOLD response to painful stimulation 
increased from the pre to post stress condition in the ACC, precuneus, thalamus and 
PAG. In the CBD and placebo conditions, the BOLD response additionally increased 
in primary motor cortex and middle temporal cortex. Placebo and CBD further 
showed increases in the primary somatosensory cortex. In the placebo and THC 
condition we found decreased activity in the frontal pole after the stressor as 
compared to before (see Figure 5a and Table 2). 
When stress-related change in the BOLD response was compared between THC and 
placebo (interaction effect drug x stress), we found that the BOLD response 
increased from pre to post stress in the left S1 in the placebo condition, while in the 
THC condition, we found the opposite effect (see Figure 5 and Table 2). We 
observed no such differences between CBD and placebo or CBD and THC. 
 
Early and late stimulation blocks 
Within pre- and post-stress phases the subjects showed a reduction of perceived 
pain intensity and unpleasantness (see above), which was modeled by comparing 
early and late stimulation blocks. In all conditions, the subjects showed significantly 
higher activation in the early than in the late stimulation blocks in the bilateral insula 
and the ACC. Significant decreases of activity in S2 were bilateral in the CBD and 
placebo condition but unilateral in the right S2 in the THC condition. In the placebo 
condition, the subjects additionally showed a significant increase in the BOLD 
response in the right middle frontal gyrus (MFG). We found no significant increases in 
the BOLD response from early to late stimulation blocks (see Figure 6a and Table 3). 
The comparison of the decreases from early to late stimulation blocks in the placebo 
and the THC conditions (interaction effect drug x time) revealed that the decrease 
was significantly higher in the right MFG and middle temporal gyrus (MTG) in the 
placebo condition compared to the THC condition (see Figure 6 and Table 3). 
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Figure 5: Change in BOLD response from pre to post stress, separately for each 
condition and compared between the placebo and THC condition: (a) Red and yellow 
voxels depict z-values of clusters with significantly increased BOLD response before 
the stressor, compared to after the stressor 
(pre(pain>baseline)>post(pain>baseline)). Blue voxels depict clusters with 
significantly increased BOLD response after the stressor, compared to before the 
stressor (pre(pain>baseline)<post(pain>baseline)). z-coordinates are in Montreal 
Neurological Institute (MNI) space. (b) Pre>Post contrast compared between drugs. 
Yellow and red voxels depict the location of a S1 cluster where the change from pre 
to post stress is different between the placebo and the THC condition. x, y, and z-
coordinates are given in MNI space. (c) illustrates the nature of the interaction 
between drug (THC vs. placebo) and stress (pre vs. post): After placebo 
administration BOLD response to painful stimulation was reduced in S1 but returned 
to baseline after the stressor. After THC administration BOLD response to painful 
stimulation was reduced after the stressor, but not at baseline before the stressor. 
Colored circles depict single subjects, black circles and black lines depict respective 
mean values. Single subject values were extracted from a 10mm sphere around the 
peak voxel of the contrast shown in Figure 5b. 
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Table 2: Activation during painful stimulation compared between the pre and post-stress phase: pre > post and pre < post, separately 
for each condition and the difference in stress related BOLD signal changes between the different conditions. Placebo(pre > p ost) ≷ 
THC(pre > post).1 
  
Brain area 
Coordinates 
(MNI 152 space) 
peak [x y z] 
Maximum 
z-value 
CBD pre(pain>baseline) > post(pain>baseline) - - - 
 pre(pain>baseline) < post(pain>baseline) Bilateral M1/ACC/Precuneous [0 -34 62] 4.37 
  Right middle temporal gyrus [56 -50 14] 3.41 
  Bilateral thalamus/PAG [-10 -28 -2] 3.53 
  Left S2/insula [-38 -20 16] 3.75 
  Right S1 [44 -22 54] 3.47 
  Left S1 [-44 -10 52] 3.85 
  Left putamen [-26 8 -4] 3.62 
  Left middle temporal gyrus [-56 -60 8] 3.44 
  Right superior temporal gyrus [48 -20 -10] 3.57 
PB pre(pain>baseline) > post(pain>baseline) Left frontal pole [-42 40 -10] 4.06 
 pre(pain>baseline) < post(pain>baseline) Bilateral ACC/Precuneous [4 -2 60] 4.58 
  Right M1 [44 -6 54] 4.26 
  Bilateral Precuneous [2 -72 34] 3.36 
  Bilateral Thalamus/PAG [8 -22 8] 4.29 
  Right lateral occipital cortex/middle temporal gyrus [56 -60 12] 3.83 
THC pre(pain>baseline) > post(pain>baseline) Left frontal pole [-40 54 8] 3.74 
  Right frontal pole [42 46 6] 3.76 
 pre(pain>baseline) < post(pain>baseline) Bilateral ACC/precuneous [-4 -2 44] 4.09 
  Bilateral thalamus/PAG [-4 -26 2] 4.13 
  Right S1 [46 -10 52] 4.27 
PB(pre(pain>baseline)<post(pain>baseline)) 
> 
THC(pre(pain>baseline)<post(pain>baseline)) 
Left S1 [-50 -30 50] 3.89 
1PB: Placebo, CBD: Cannabidol, THC: Tetrahydrocannabinol, M1: Primary motor cortex, ACC: anterior cingulate cortex, S1/S2: Primary and 
secondary somatosensory cortex, PAG: periaqueductal grey.  
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Figure 6: Change in BOLD response from early to late stimulation blocks, separately 
for each condition and compared between the placebo and THC condition. (a) Red 
and yellow voxels depict clusters with significantly increased BOLD response in early 
pain trials, compared to late pain trials (early(pain>baseline)>late(pain>baseline)). 
Blue voxels depict clusters with significantly increased BOLD response in late 
stimulation trials, compared to late stimulation trials 
(early(pain<baseline)>late(pain<baseline)). z-coordinates are Montreal Neurological 
Institute (MNI) coordinates. (b) Early>Late contrast compared between drugs. Left: 
Yellow and red voxels depict the location of a cluster in the middle frontal gyrus 
(MFG) where the change from early to late pain stimulation trials is different between 
the placebo and the THC condition. x, y, and z-coordinates are given in MNI space. 
Right: The graph illustrates the nature of the interaction between drug (THC vs. 
placebo) and stress (early vs. late): After placebo administration BOLD response to 
painful stimulation was increased in MFG in early, but not late pain stimulation trials. 
After THC administration BOLD no such early/late difference was observed. Colored 
circles depict single subjects, black circles and black lines depict respective mean 
values. Single subject values were extracted from a 10mm sphere around the peak 
voxel of the contrast shown in Figure 8a. (c) Left: Yellow and red voxels depict the 
location of a cluster in the middle temporal gyrus (MTG) where the change from early 
to late pain stimulation trials is different between the placebo and the THC condition. 
x, y, and z-coordinates are given in MNI space. Right: The graph illustrates the 
nature of the interaction between drug (THC vs. placebo) and stress (early vs. late): 
After placebo administration BOLD response to painful stimulation was increased in 
MTG in early, but not late pain stimulation trials. After THC administration BOLD no 
such early/late difference was observed. Colored circles depict single subjects, black 
circles and black lines depict respective mean values. Single subject values were 
extracted from a 10mm sphere around the peak voxel of the contrast shown in Figure 
8b. PSC: percent signal change; MFG: Middle frontal gyrus; MTG; Middle temporal 
gyrus; CBD: Cannabidiol; THC: Tetrahydrocannabinol; 
Original contributions 
43 
Table 3: Activation during painful stimulation compared between the early and late stimulation phase: early > late and early < late, 
separately for each condition and the difference in habituation related BOLD signal changes between the different conditions. 
Placebo(early > late) ≷ THC(early > late). 1 
  
Brain area 
Coordinates 
(MNI 152 space) 
peak [x y z] 
Maximum 
z-value 
CBD early(pain>baseline) > late(pain>baseline) Right insula/S2 [58 12 0] 3.9 
  Left insula/S2 [-38 2 -6] 3.55 
  ACC/M1 [2 -10 60] 3.25 
 early(pain>baseline) < late(pain>baseline) - - - 
Placebo early(pain>baseline) > late(pain>baseline) Right insula/S2/MFG  [60 -18 28] 4.55 
  ACC/M1 [-2 -10 48] 4.05 
  Right precuneous [10 -74 40] 3.89 
  Left insula/S2 [-62 -18 16] 4.11 
 early(pain>baseline) < late(pain>baseline) - - - 
THC early(pain>baseline) > late(pain>baseline) Right insula/S2 [34 8 8] 4.54 
  Right M1 [22 -32 68] 3.69 
  ACC [-6 34 6] 3.34 
  Left insula  [-36 -16 6] 4.05 
 early(pain>baseline) < late(pain>baseline) - - - 
PB(early(pain>baseline)>late(pain>baseline)) 
> 
THC(early(pain>baseline)>late(pain>baseline)) 
right MFG [48 38 18] 3.58 
right MTG [68 -46 -4] 4.1 
1PB: Placebo, CBD: Cannabidol, THC: Tetrahydrocannabinol, M1: Primary motor cortex, ACC: anterior cingulate cortex, S2: Secondary 
somatosensory cortex, MFG: Middle frontal gyrus, MTG: middle temporal gyrus. 
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Discussion and conclusions  
This study aimed to investigate the effects of THC and CBD on stress-induced 
inhibition of pain. SIA and habituation to pain were compared between a THC, CBD 
and a placebo condition. 
The stress ratings, heart rate and blood pressure indicated that the cognitive stress 
plus noise induced significant stress. Perception and pain thresholds as well as 
tolerance levels and pain ratings were reduced after the stressor. On the neuronal 
level, the SIA effect was accompanied by a reduction of the BOLD response in the 
bilateral frontal pole and an increase in the ACC, precuneus, thalamus and PAG 
after, compared to before the stressor. In the placebo condition the BOLD response 
to painful stimulation increased from pre to post stressor in the ipsilateral S1, while no 
such increase was found for THC. However, neither THC nor CBD altered the sub- or 
suprathreshold pain perceptions post stress. Additionally, we observed that THC 
interfered with the decrease of self-reported pain levels to repetitive painful 
stimulation that could be observed in the placebo and CBD condition. In the placebo 
condition unpleasantness ratings of painful electric stimulation showed a stronger 
decrease from early to late stimulation trials than in the THC condition. In the placebo 
condition this habituation to the painful stimulus was accompanied by decreases of 
the BOLD response in the MFG and MTG from early to late stimulation trials. In the 
THC condition no such decrease was observed. 
 
Stress-induced analgesia 
Our data on SIA after systemic administration of different cannabinoid agents have 
multiple implications. First, we successfully induced stress and SIA in the placebo 
condition. This SIA response was accompanied by activation of ACC, precuneus, 
thalamus and PAG, in accordance with previous human work that showed 
involvement of the ACC [76]. Animal work has further shown the involvement of PAG 
activity in the descending inhibition of pain. Electrical stimulation of the ventrolateral 
PAG reduced pain sensitivity in formalin and tail-flick test in rats [22]. The injection of 
an opioid receptor antagonist [70] suppressed SIA, thereby confirming PAG 
involvement in SIA.  
Our second finding relating to SIA was that, in the ipsilateral S1, the change in 
activity from pre to post stress differed between placebo and THC. This result was 
mainly driven by a decrease of activity in the placebo condition before the stressor. 
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Under THC we did not observe similar changes (see Figure 6b). A deactivation of S1 
in response to pain has been found in studies using tonic painful stimulation, such as 
3 minutes of a hot water bath in humans [5] or 7 seconds of mechanical stimulation in 
squirrel monkeys [64]. This deactivation has been related to the inhibition of tactile 
sensitivity in S1 cortex [15]. Further, it is important to note that the deactivation we 
found was ipsilateral to the stimulated body site. Interhemispheric inhibition in 
ipsilateral S1 has been shown in a study using median nerve stimulation in human 
subjects [55]. Together with the high density of CB1 receptors in S1 [29; 65], this 
suggests that THC might interfere with interhemispheric inhibitory processes. 
Our third finding related to SIA was the lack of modulation of SIA by the 
administration of THC or CBD. This was unexpected, since studies in rodents have 
shown that the suppression of endocannabinoid signaling by injection of rimonabant, 
a CB1 receptor antagonist, into the basolateral amygdala [17], the dorsolateral PAG 
or RVM [61] suppressed SIA, while increased endocannabinoid signaling induced by 
increasing 2-AG concentrations in the ventrolateral PAG enhanced SIA [31]. We 
could not translate these findings to the endocannabinoid system in humans. High 
interspecies overlaps in CB1 receptor distribution in neocortex, primary 
somatosensory cortex, amygdala and PAG [30] make it unlikely that interspecies 
differences are responsible for the discrepancy between our human and previous 
work done in rodents. It is possible that the type of stressor contributed to these 
differences. The cognitive stressor we used has repeatedly been employed to induce 
stress in humans [2; 38; 67]. This type of continuous stressor may differ in the 
involvement of the cannabinoid system similar to differences of involvement of the 
opioid system in analgesia [42]. Previous animal studies used brief painful foot 
shocks to induce stress and measured pain thresholds, for example, by the use of 
the tail-flick, to quantify the SIA effect [17; 31; 61]. This procedure of stimulating at 
one body site and measuring pain thresholds at another, however, may involve 
central habituation to painful stimulation, which have been shown in humans, where 
repetitive painful stimulation led to pain attenuation in a non-stimulated limb [56] and 
pain attenuation was accompanied by activation in pain processing areas, such as 
thalamus, insula, SII and the putamen, while activity in the rostral ACC, an area 
involved in endogenous pain control, increased over time [12]. It therefore seems 
likely that the habituation-like non-associative learning effect in our painful 
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stimulation, but not the effects induced by our cognitive stressor, resemble the effects 
found in previous studies on SIA. 
 
Non-associative learning/habituation effects 
In our experiment, habituation to painful stimulation was impaired when THC, a CB1 
receptor agonist, was administered. This effect was represented on the affective 
rather than the sensory dimension of pain, which is in line with previous work that has 
related the pain modulatory effects of THC to the affective-motivational component of 
pain [41]. Habituation was accompanied by decreases in the BOLD response in pain-
related areas such as SII and Insula, which have previously been shown to decrease 
with habituation to pain [12]. As mentioned above, the habituation to pain in our study 
might resemble the effects found in previous studies on SIA, as they had used painful 
stimulation as a stressor. Therefore the analgesic effect of the stressor may have 
acted via central habituation to painful stimulation. The endocannabinoid system has 
repeatedly been linked to memory and learning mechanisms [1; 36]. Habituation, as 
a form of non-associative learning, has been associated with the CB1 receptor which 
mediates fear extinction via habituation processes, as shown in CB1 knockout mice, 
which were impaired in habituation of the fear response to a tone after sensitization 
with an inescapable footshock [33; 34]. 
Further, we found that, in the MFG and MTG, the change in activity from early to late 
stimulation differed between placebo and THC. In both cases this reflects an early 
activation in the placebo condition which returns to baseline during late stimulation. 
Initial activation and therefore also the reduction of activity over time were not present 
in the THC condition. A review of 34 conditioning study revealed MFG as consistently 
being engaged in high-threat processing [53]. Further, MFG was suggested to be 
suppressed in response to emotional distractors [75] and in response to an emotional 
scene, when the attention was targeted elsewhere [25]. The right MFG has 
repeatedly been associated with response inhibition, for example in Go/NoGo tasks, 
with a major role in monitoring and directing attention [62]. Damage to that area 
significantly attenuated the reaction time to a stop signal in a human lesion study [6]. 
The MTG and MFG have further been associated with semantic memory retrieval 
[27] and shown to have interconnectivity with the executive control network (ECN) 
[73]. The administration of THC may therefore have interfered with a monitoring and 
retrieval network involving inhibitory control over threatening stimuli. Since these 
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findings were not predicted in our study on SIA, future research should (1) determine 
the reproducibility of our findings on habituation and (2) clarify the neuronal 
mechanisms involved. Attentional, memory and emotional networks may all play 
important roles and have all been associated with cannabinoid signaling. 
 
Limitations 
For most participants, neither THC nor CBD blood concentrations showed a peak at 
t1, in contrast to blood concentrations at t2. The time between blood samples at t1 
and the beginning of the SIA experiment was approximately 16 minutes. Hence, 
more frequent blood sampling would have been desirable. Previous studies have 
shown clear drug effects after oral administration of the same doses between one 
and two hours after substance administration [10; 11; 71], and the blood levels in our 
experiment showed a peak at the end of the experiment. Thus, the time window for 
our experiment should still have been appropriate. 
Future studies could clarify the nature of these effects by including additional study 
arms. Cannabinoids have been shown to be involved in placebo analgesia [9], a 
natural history condition without drug/placebo administration could therefore control 
for placebo effects. Including different types of stressors and a condition without 
stress could furthermore clarify the analgesic mechanisms that THC interfered with in 
our study. 
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2.2 The impact of controllability on pain and suffering2 
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(2018). The impact of controllability on pain and suffering. Pain reports, in revision 
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Abstract 
Introduction: Chronic pain and pain-related suffering are major health problems. 
The lack of controllability of experienced pain seems to greatly contribute to the 
extent of suffering. This study examined how controllability affects the perception of 
pain and pain-related suffering, and the modulation of this effect by beliefs and 
emotions such as locus of control of reinforcement, pain catastrophizing, and fear of 
pain. 
Methods: Twenty-six healthy subjects received painful electric stimulation in both 
controllable and uncontrollable conditions. Visual analogue scales and the “Pictorial 
Representation of Illness and Self Measure” (PRISM) were used to assess pain 
intensity, unpleasantness, pain-related suffering and the level of perceived control. 
We also investigated nonverbal indicators of pain and suffering such as heart rate, 
skin conductance and corrugator electromyogram. 
Results: Controllability selectively reduced the experience of pain-related suffering, 
but did not affect pain intensity or pain unpleasantness. This effect was modulated 
chance locus of control but was unrelated to fear of pain or catastrophizing. 
Physiological responses were not affected by controllability. In a second sample of 
twenty-five participants we varied the instruction to reflect less personal involvement 
in controllability of the pain. The effect of controllability on pain-related suffering was 
only present when a high degree of personal emotional involvement was implied. 
Discussion: Our data suggest that the additional measure of pain-related suffering 
may be important in the assessment of pain and may be more susceptible to the 
effects of perceived control than pain intensity and unpleasantness. We also show 
that this effect depends on personal involvement. 
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Introduction 
Pain perception is modulated by cognitive and emotional variables such as 
predictability [12,38], controllability [7,57], attentional focus [1,46], or fear of pain 
[30,43,44]. Studies in healthy volunteers showed that controllable situations reduce 
pain intensity [7,39,57] and unpleasantness [7], however, controllability did not 
always change pain perception [20,27,47]. Although actual control was more 
effective than perceived control alone in reducing pain [39], this dissociation cannot 
fully explain these ambiguous findings, as exerted control did not reduce pain 
intensity [56] and perceived control was found to decrease pain intensity [7] in other 
studies. Anxiety [56], helplessness [57] or pain unpleasantness [7] were not 
assessed consistently across studies, although these variables may modulate the 
effects of control on pain perception. Carnevale [13] suggested that suffering is the 
most important factor that drives patients to seek medical attention. This is also true 
for patients with chronic pain [3]. We have demonstrated that pain-related suffering is 
an additional component of pain that can be assessed independently of pain intensity 
and unpleasantness [10]. The lack of controllability might be especially important for 
the experience of pain-related suffering in both experimental pain studies and in 
patients [6,16]. Ongoing but unsuccessful efforts to influence the pain make patients 
especially vulnerable to suffering [53]. In addition to observing the effects of control 
on verbal reports of pain and suffering, a secondary goal of the study was to see if 
there are also effects on physiological indicators of pain and suffering such as skin 
conductance responses (SCR), corrugator electromyogram (EMG) and heart rate 
(HR) [8]. This would indicate multi-level effects and would permit bias-free 
assessments of pain and suffering also in groups that may not easily give verbal 
reports such as children or incapacitated persons. 
The effect of the experimental manipulation of controllability is modulated by 
individual differences in the perception of control. Wiech et al. [56] reported that 
exerted control over painful stimulation led to reduced pain perception in half of the 
subjects while the other half showed increased pain intensity ratings. The authors 
hypothesized that the individuals’ locus of control might explain these inter-individual 
variations. We therefore examined locus of control of reinforcement, which is the 
degree to which people believe that they have control over the outcome of positive or 
negative events in their lives as opposed to external forces beyond their control 
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[34,35,45]. We hypothesized that an internal locus of control would modulate higher 
effects of uncontrollability on pain than an external or chance locus of control. 
The current study examined the influence of controllability on pain intensity, 
unpleasantness and pain-related suffering in two experiments that differed in the 
level of personal involvement. We hypothesized that control over pain would 
positively affect all three dimensions, with the strongest reduction related to suffering. 
We expected reductions in SCR and EMG, but not HR. A high chance locus of 
control, the belief that powerful others control one’s life, high catastrophizing and high 
fear of pain were assumed to reduce the positive effects of perceived control on 
suffering. 
 
Methods 
Participants 
Twenty-six right-handed subjects (13 male) between 18 and 43 years of age (mean: 
25.5, standard deviation (SD) = 5.81) participated in the study (sample 1). Twenty-
five right-handed subjects (8 male) between 20 and 49 years of age (mean: 25.32, 
SD = 5.79) participated in study 2 (sample 2). Sample sizes were based on power 
calculations to detect large effects (effect size d>0.5) in a within-subjects comparison, 
which have previously been reported in a similar study design [57]. The Ethics 
Committee of the Medical Faculty Mannheim, University of Heidelberg, Germany, 
approved the study and written informed consent was obtained from each participant. 
Exclusion criteria were cardiovascular or neurological disorders, brain injury, acute or 
chronic pain, current use of pain medication, pregnancy, lifetime and current 
substance abuse or dependence and any other mental disorders. The subjects were 
screened by a psychologist using the German version of the Structured Clinical 
Interviews for the Diagnostic and Statistical Manual IV (SCID) [58] Axis I to exclude 
subjects who fulfilled the criteria for a mental disorder. 
 
Apparatus and application of painful stimuli 
Pain processing was investigated in response to a series of painful electrical stimuli 
applied under conditions of controllability vs. uncontrollability. A pair of subcutaneous 
needle electrodes (20 mm long, 0.35-mm uninsulated tip, 2-mm² stimulation area, 
model: 9013R0272, 28G, Alpine Biomed ApS, Skoviunde, Denmark) were placed at 
the left upper back, at the mid-trapezius muscle, (1mm needle separation). The 
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stimulation site was chosen to mimic a clinical condition, like chronic back pain as 
closely as possible under experimental conditions and to allow similar experiments in 
chronic back pain patients. Needle electrodes mainly activating Aδ fibers [26] were 
chosen to elicit a rapid and sharp painful sensation. The invasive character of these 
needles was also expected to result in sufficiently high suffering ratings to avoid floor 
effects in the rating data. Electric stimuli (2ms stimulus duration, 400V, inter stimulus 
interval 500ms) were applied using a constant current stimulator (model DS7A; 
Digitimer, Hertfordshire, England). The experiment was performed using 
Presentation® software (Version 14.0, http://www.neurobs.com). 
 
Psychophysical thresholds and stimulus calibration 
The electrical stimulation parameters were determined individually, first by assessing 
pain-related thresholds by the method of limits. For this purpose, perception 
threshold, pain threshold and pain tolerance were assessed during four ascending 
series of electric stimuli. The participants were instructed to press a button when they 
felt the stimulus for the first time (perception threshold), when the stimulus was 
painful for the first time (pain threshold) and when they could no longer tolerate the 
stimulus intensity (pain tolerance). Each threshold was acquired once per ascending 
series. The first ascending series was discarded as a practice trial, to exclude early 
fatigue and/or sensitization. Thus, the average of 3 ratings per threshold served as 
the final parameter. A painful stimulus intensity was preset at 70% of the interval 
between pain threshold and pain tolerance. 
Next, the painful stimulus intensity was adjusted to a perceived pain intensity of 70% 
on a visual analogue scale (VAS) with the endpoints “no pain” (0) to “extreme pain” 
(100). Magnitude estimates of pain intensity were assessed during three test trials 
(duration 10 seconds each). Stimulus intensity was adjusted to reach a VAS rating of 
about 70%. The resulting individual stimulus intensity of each subject was used for all 
further procedures (sample 1: mean: 8.75, SD = 11.2; sample 2: mean: 10.35, SD = 
18.38, values in mA). 
 
Experimental procedure 
We employed a within-subjects design, where each subject received painful electric 
stimulation in a controllable and an uncontrollable condition. The experiment 
consisted of four blocks in which participants received eight series of painful 
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stimulations (see Figure 1a). Each of the four blocks comprised four controllable and 
four uncontrollable trials, which were presented in an intermixed order (randomized 
within each block). 
In the controllable condition, the participants had the possibility to stop the painful 
electric stimulation via a button press. They were instructed to press the button when 
the stimulation became intolerable. In the uncontrollable condition, the participants 
were informed that the duration of the stimulation was randomly determined by the 
computer. In reality, we used a yoked control design to match the length of the 
stimulations in the uncontrollable condition with those in the controllable condition 
[57]. The duration of the four uncontrollable trials was predetermined by the duration 
of the four controllable trials of the preceding block. The first block started with a 
controllable trial. Durations of the uncontrollable trials of the first block were 
predetermined randomly by one of the preceding controllable trials of the same block. 
This led to comparable durations of the controllable and uncontrollable trials (sample 
1: controllable: 22.8 ± 19.03 sec, uncontrollable: 22.33 ± 18.33 sec; sample 2: 
controllable: 16.9 ± 15.05 sec, uncontrollable: 18.2 ± 15.28 sec). The blocks were 
separated by 1-minute breaks. 
Due to our experimental manipulation, the exerted control had to be accompanied by 
increased perceptions of control in the controllable trials. We therefore assessed 
perceived controllability of the pain during the controllability and uncontrollability trials 
after each block of 8 trials. The same VAS was used for the controllable and 
uncontrollable trials. The VAS was 800 pixels (23.5 cm) long and ranged from “not at 
all controllable” to “extremely controllable”, with a visual angle of 16.7°. The pixels 
were linearly transformed to values of 0 to 100. Perceived controllability differed 
significantly between the controllable and uncontrollable conditions (sample 1: 
t(25)=12.91, p<.001, d=2.53; sample 2: t(24)=6.96, p<.001, d=1.39). The participants 
rated perceived controllability higher when they were able to stop the stimulation 
compared to the uncontrollable condition. 
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Figure 1: Structure of the experiment: (a) The experiment consisted of four blocks with eight stimulation trials each. In half of the 
cases, the stimulation could be stopped by the participant (controllable condition). The remaining trials were stopped by the  computer 
(uncontrollable condition). The duration of the self-controlled trials equaled the duration of the computer-controlled trials in the 
subsequent block (dotted arrows). The order of the trials was randomized within each block. (b) Each trial was announced by a  slide 
that indicated the type of the trial. Note that in 25 participants the word ‘self’ was replaced by the word ‘button press’ to a nnounce the 
controllable trials. The anticipation phase was followed by a varying interval of painful stimulation, ratings of pain intensity, pain 
unpleasantness and pain-related suffering. Each trial ended with an off-block lasting 12 seconds (sec). ISI: inter stimulus interval, sec 
seconds, msec: milliseconds. 
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Instructions and trial structure 
In each trial the condition was announced on the computer screen during a four 
seconds prestimulus time span. The stimulus was expected during the following six 
seconds of an anticipation phase. Controllable trials were announced during the 
prestimulus interval with the words: “SELF; please press the button to terminate the 
stimulation”. Uncontrollable trials were announced, for four seconds, with a slide 
stating: “COMPUTER; stimulation will be terminated by the computer”. The 
assessment of perceived stimulus intensity, unpleasantness and related suffering on 
a VAS, as well as the PRISM task, providing an alternate estimate of suffering, were 
presented in random order after each trial. The participants had a 32-second time 
frame to rate all four scales, followed by a resting time span (off block) of 12 seconds. 
 
Ratings 
The assessment of pain intensity, unpleasantness and suffering was performed on 
horizontal visual analogue scales (800 pixels = 235 mm) with appropriate endpoints 
(pain intensity: “no pain” and “extreme pain”; pain unpleasantness: “not unpleasant” 
and “extremely unpleasant”; suffering: “no suffering” and “extreme suffering”). The 
scales were presented on a computer screen at a distance of 800 mm and comprised 
an angular view of 16.7°. The VAS ratings were transformed to values ranging from 0 
to 100. 
In the absence of a gold standard on how to measure suffering [9], we 
complemented the “suffering” VAS with the suffering scale implemented in the 
“Pictorial Representation of Illness and Self Measure” (PRISM), because it performed  
best on quality criteria compared to other instruments for measuring suffering [33]. 
The PRISM task was presented as a computerized version of the original task. The 
participants viewed a grey screen with a fixed yellow circle in the bottom right corner, 
representing their self. A moveable red circle was located in the center of the screen, 
representing the current painful stimulation (corresponding to “illness” in the original 
PRISM task). The participants were instructed to estimate the importance of the 
painful stimulation in their life by placing the red circle in an appropriate distance to 
the yellow circle. According to the PRISM rationale, the amount of suffering is coded 
by the inverse of the distance of the centers of the red and yellow circles. Thus, the 
closer the red circle (painful stimulation) is found in relation to the yellow circle (self), 
the higher is the suffering felt under the aversive stimulation while the further the red 
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circle is away from the yellow circle, the lower is the suffering indicated. The raw 
PRISM scale values were linearly transformed to values ranging from 0 to 100, with 0 
representing no and 100 representing maximal suffering. 
Before the experiment, all participants were asked if they were able to discriminate 
between the ratings. Since suffering is a personal and individual experience 
conveying multiple meanings which we did not want to delimit [14], no definition was 
given to the participants. If the participants struggled with differentiating between 
suffering and any of the pain scales, they were asked: “Do you think one can suffer 
without being in pain – can you give an example?” and “Do you think one can be in 
pain without suffering – can you give an example?”. All participants confirmed those 
questions and were able to give examples. If participants struggled with the 
discrimination of pain intensity and pain unpleasantness, it was explained to them by 
using the radio metaphor by Price et al. (1983) [41]. In this metaphor experiencing 
pain is compared to listening to the sound of a radio, where pain intensity refers to 
the loudness of the music and pain unpleasantness refers to the quality of the music 
played. The participants had a practice run for each rating before the experiment 
commenced. 
 
Adjustment of the experimental procedure 
This experiment was initially performed in 26 participants. During the debriefing 
session after the experiment, four participants reported being confused by the 
overlap between the PRISM rating and the instructions. The controllable trials were 
announced with the word ‘self’, while during the PRISM task the participants had to 
place a token of the painful stimulation in relation to their self (yellow circle), with 
closer placements representing higher suffering.  
The participants stated that, in the PRISM task, they were confused between two 
possible meanings of the word “self” on the display and did not know whether they 
were expected to rate the amount of their own suffering (with ratings closer to the 
self, indicating higher suffering) or how much they felt being the agent in control of 
the previous stimulation (with ratings closer to the self, indicating higher agency).  
This instruction-related issue was not anticipated and therefore not systematically 
assessed in all participants. It can hence not be ruled out that other participants were 
having the same problem without reporting it. This renders a subsample analysis 
impossible and PRISM ratings in this sample should therefore be interpreted with 
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caution. To rule out this ambiguity, the experiment was repeated in another 25 
participants. For those 25 participants the general instructions before the experiment 
were changed and referred to controllable trials as ‘stoppable by a button press’. 
Controllable trials were announced with a slide stating: “BUTTON PRESS; please 
press the button to terminate the stimulation”) and uncontrollable trials with the 
following slide: “COMPUTER; stimulation will be terminated by the computer”). The 
data of the second experiment (sample 2) were analyzed in the same way as the 
initial experiment (sample 1). 
 
Questionnaires 
Prior to the experiment, the participants completed the Locus of Control Scale [32], 
which assesses beliefs about control of reinforcement with the subscales chance 
(IPC-C), control by powerful others (IPC-P), and perceived mastery over one's 
personal life (IPC-I). The scale has good test-retest-reliability (IPC-I: r=.55, IPC-P: 
r=.66 and IPC-C: r=.70), internal consistency (α=.91, for IPC-I, α=.95 for IPC-P and 
α=.9 for IPC-C) and validity [31]. A general locus of control scale was chosen 
because we examined healthy individuals and the painful stimulation was not related 
to any health problem [54]. 
The participants also completed the Pain-Related Self Statements Scale (PRSS, 
[22]), which assesses catastrophizing and active coping. The scale is validated in 
German participants and has excellent reliability (α=.92 for catastrophizing and α=.88 
for active coping) and validity, as shown by significantly higher values for pain 
catastrophizing and significantly lower values for active coping in pain patients 
compared to healthy controls, and low to moderate correlations with other pain-
related variables such as amount of daily activity, affective distress or pain severity. 
Furthermore, the participants completed the Fear of Pain Questionnaire (FPQ-III). 
The FPQ-III is a self-report measure designed to evaluate fears about severe, minor, 
and medical pain with higher scores indicating more fear. The FPQ-III has shown to 
be a valid and reliable instrument with good test-retest reliability, predictive validity, 
and internal consistency (for severe pain: α=.88, r=.69, for minor pain: α=.87, r=.73 
and for medical pain α=.87, r=.76) [37,49] and has been validated in a German 
population. The PRSS and FPQ-III were chosen to allow for comparison with 
previous experimental work on pain-related suffering [8,10] and because they exist in 
validated German versions. 
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Physiological assessments 
Electromyography (EMG), skin conductance responses (SCR) and electrocardiogram 
(ECG) were recorded and amplified using a BrainAmp ExG amplifier (Brain Products 
GmbH, München, Germany) and registered with a sampling frequency of 500 Hz. 
The data in one participant had to be discarded due to technical problems. 
EMG activity was recorded from the musculus corrugator supercilii using small 
surface electrodes (1.5mm Ag/AgCl) that were placed in a bipolar fashion above the 
left eye, using the placement recommended by Fridlund and Cacioppo [24]. The 
SCRs were recorded from two electrodes (5mm Ag/AgCl), which were placed on the 
medial phalanges of digits III and IV of the left hand [4]. SCR analysis was performed 
using the Ledalab V3.4.6c software package for Matlab and followed the guidelines 
of Fowles et al. [23]. ECG was recorded using two 7-mm Ag/AgCl electrodes 
(Asmuth GmbH Medizintechnik, Minden, Germany), placed on the subjects’ left 
lateral sternum at the upper and lower edges of the musculus pectoralis major. The 
ground electrode was placed on the right hip bone. Calculation of interbeat latencies 
and artefact correction were performed by the KubiosHRV software [50]. Details on 
preprocessing of the physiological data can be found in the supplementary material. 
 
Statistical analysis 
As explained in the methods section, two samples were assessed in two separate 
experimental runs, with differing instructions for the controllability condition. In the 
original sample (sample 1) the instructions referred to controllable trials as being 
stoppable by the participant. In the sample of the second experiment (sample 2) the 
instructions were changed and referred to controllable trials as ‘stoppable by a button 
press’. All results are reported for both experimental runs. Statistical analyses were 
performed using RStudio 1.0.143 (RStudio, Inc.) with R 3.4.0 (The R Foundation for 
Statistical Computing). 
 
Controllability and its influence on pain and suffering 
To test the specificity of the effect of controllability on suffering compared to pain 
intensity and pain unpleasantness, we used an analysis of variance to examine the 
within-subject effects of controllability (controllable versus uncontrollable) and rating 
dimension (intensity versus unpleasantness versus suffering VAS versus PRISM). 
Effect sizes for the ANOVAs are reported as Cohen’s d. We used pairwise post-hoc t-
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tests (false discovery rate, FDR [5] corrected) to compare the VAS ratings for 
perceived controllability, pain intensity, unpleasantness and suffering as well as 
PRISM ratings in the controllable and uncontrollable conditions. Effect sizes for the t-
tests are reported as Cohen’s d. 
 
Individual differences in the effects of controllability on pain and suffering 
To explore the impact of locus of control, fear of pain and pain catastrophizing on the 
effect of controllability, the IPC, FPQ-III and PRSS subscales and the difference in 
ratings (controllable minus uncontrollable) were correlated for each rating (intensity, 
unpleasantness, suffering VAS, PRISM). 
 
Sample differences in the effects of controllability on pain and suffering 
To explore sample differences in the effect of controllability on the ratings, we 
implemented separate analyses of variance for each rating dimension (pain intensity, 
unpleasantness, suffering VAS and PRISM) to test the interaction of sample (sample 
1 versus sample 2) and controllability (controllable versus uncontrollable). To 
examine the association of enduring beliefs and pain controllability, we compared the 
correlations of the IPC, FPQ-III and PRSS subscales with differences in controllability 
(controllable minus uncontrollable) between samples using Fishers’z. 
 
Physiological assessments 
For details on statistical analysis of physiological data see supplementary material. 
 
Results 
Controllability and its influence on pain and suffering 
The analyses of variance using controllability (controllable versus uncontrollable) and 
the rating dimension (intensity versus unpleasantness versus suffering VAS versus 
PRISM) as within subject effects were significant for rating dimension (sample 1: 
F(3,75)= 15.41, p<.001, d=1.1; sample 2: F(3,72)= 24.47, p<.001, d=1.43) with lower 
suffering than intensity and unpleasantness ratings. The main effect of controllability 
was not significant in this analysis (sample 1: F(1,25)=0.40, p=.53, d=.03; sample 2: 
F(1,24)=0.93, p=.34, d=.07), however, we found a significant interaction for 
controllability X rating dimension (sample 1: F(3,75)=6.59, p<.001, d=.12; sample 2: 
F(3,72)=5.69, p=.001, d=.11). This illustrates a reduction of suffering VAS 
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(t(25)=3.42, p=.008, d=.67) in the controllable condition of sample 1, which was not 
present in the intensity (t(25)=-1.37, p=.26, d=.27), unpleasantness (t(25)=-1.33, 
p=.26, d=.26) and PRISM (t(25)=0.31, p=0.75, d=.06) ratings (see Figure 2a). For 
sample 2, it illustrates an increase of unpleasantness ratings in the controllable 
condition (t(24)=-2.11, p=.04, d=.42), which was not present in the intensity (t(24)=-
1.76, p=.09, d=.35), suffering VAS (t(24)=0.78, p=.44, d=.15) and PRISM ratings 
(t(24)=0.18, p=.85, d=0.03), (see Figure 2b). 
 
Figure 2: Effect of controllability on ratings in the original sample (a) and the second 
experiment (b): Bars show mean pain intensity, pain unpleasantness, suffering VAS, 
and PRISM rating for the controllable (white) and the uncontrollable (black) condition, 
error bars depict the standard error of the mean. Asterisks show significant repeated-
measures t-tests (controllable vs. uncontrollable) with *p<.05 and **p<.01. VAS: 
visual analogue scale; PRISM: Pictorial Representation of Illness and Self Measure.
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Table 1: Pain and suffering scales within experimental conditions: Intensity, unpleasantness, suffering and PRISM ratings and ratings 
of perceived controllability are shown over all conditions.1 
Sample Condition 
Sample 
size 
(n) 
Perceived 
controllability 
Intensity 
Unpleasant
ness 
Suffering PRISM 
M±SD M±SD M±SD M±SD M±SD 
Sample 1 
(personally 
relevant) 
controllable 26 90.89±11.05 59.46±16.78 66.71±19.08 32.35±21.91 63.47±31.66 
uncontrollable 26 26.09±20.57 57.88±17.51 65.02±19.32 37.43±23.34 64.01±29.13 
significance  *** n.s. n.s. ** n.s. 
        
Sample 2 
(impersonal) 
controllable 25 84.83±13.11 62.34±17.62 62.14±18.63 30.16±19.7 69.02±26.85 
uncontrollable 25 41.56±28.17 59.8±17.41 57.89±18.36 31.27±19.93 69.34±25.96 
significance  *** n.s. * n.s. n.s. 
1 M: mean, SD: standard deviation, PRISM: Pictorial Representation of Illness and Self Measure, ***p<.001, **p<.01, *p<.05, n.s .: 
p>.05. 
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Individual differences in the effects of controllability on pain and suffering 
Subjects with a high chance-related locus of control showed significantly more 
reduction in suffering VAS ratings in sample 1 (rp(24)=-.42, p=.03), but less reduction 
in suffering VAS (rp(23)=0.49, p=.03) and suffering as assessed with the PRISM 
(rp(23)=0.53, p=.02) in sample 2 in the controllable versus uncontrollable trials (see 
Figure 3). There was no significant influence of chance-related locus of control on the 
effect of experimental control for pain intensity (sample 1: rp(24)=-.38, p=.08; sample 
2: rp(23)=0.35, p=.08), unpleasantness (sample 1: rp(24)=-.28, p=.17; sample 2: 
rp(23)=0.42, p=.05) and also not for PRISM ratings in sample 1 (rp(24)=-.02, p=.92). 
There was no significant effect of internal locus of control, locus of control directed to 
powerful others, catastrophizing, active coping or fear of minor, severe or medical 
pain on the difference between controllable and uncontrollable condition (all r<.35, 
p>.18). 
 
Figure 3: Impact of attributional style on the effects of control in the original sample 
(a) and the second experiment (b): the x-axis shows the chance subscale of the IPC. 
The y axis shows the difference (Δ) in the suffering VAS ratings. Ratings in the 
uncontrollable condition were subtracted from ratings in the controllable condition. 
The black triangles depict the participants who indicated more suffering when pain 
could not be controlled. The grey triangles depict participants who indicated more 
suffering when pain could be controlled. IPC-C: Chance subscale of the internal, 
powerful others and chance scale, *p<.05. 
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Table 2: Correlations of attributional style, coping strategies and fear of pain with differences in ratings (controllable minus 
uncontrollable) for each rating (intensity, unpleasantness, suffering VAS, PRISM1 
 Sample 1 (personally relevant) Sample 2 (impersonal) 
 
Intensity 
Unpleasant
ness 
Suffering 
VAS 
PRISM Intensity 
Unpleasant
ness 
Suffering 
VAS 
PRISM 
 r(24); p r(24); p r(24); p r(24); p r(23); p r(23); p r(23); p r(23); p 
IPC: Internal 
r=-.18 
p=.38 
r=-.03 
p=.86 
r=.2 
p=.33 
r=-.27 
p=.19 
r=.06 
p=.76 
r=-.15 
p=.76 
r=-.21 
p=.76 
r=-.11 
p=.76 
IPC: Powerful 
Others 
r=-.23 
p=.25 
r=-.02 
p=.91 
r=-.16 
p=.43 
r=-.04 
p=.86 
r=.06 
p=.95 
r=.35 
p=.33 
r=.01 
p=.95 
r=.15 
p=.92 
IPC: Chance 
r=-.38† 
p=.08 
r=-.28† 
p=.17 
r=-.42*† 
p=.03 
r=-.02† 
p=.92 
r=.35 
p=.08 
r=.42 
p=.05 
r=.49* 
p=.03 
r=.53* 
p=.02 
         
PRSS: 
Catastrophizing 
r=-.13 
p=.95 
r=.21 
p=.95 
r=-.01 
p=.96 
r=.08 
p=.95 
r=-.08 
p=.7 
r=-.16 
p=.61 
r=-.16 
p=.61 
r=-.24 
p=.61 
PRSS: Coping 
r=.09 
p=.87 
r=.22 
p=.54 
r=.01 
p=.96 
r=-.25 
p=.54 
r=.24 
p=.38 
r=.26 
p=.38 
r=.22 
p=.38 
r=-.02 
p=.93 
         
FPQ: minor 
r=-.23 
p=.35 
r=-.24 
p=.35 
r=-.27 
p=.35 
r=-.12 
p=.55 
r=-.04 
p=.83 
r=.15 
p=.63 
r=.23 
p=.63 
r=.15 
p=.63 
FPQ: severe  
r=-.31 
p=.47 
r=-.1 
p=.63 
r=.15 
p=.62 
r=-.2 
p=.62 
r=.04 
p=.86 
r=.12 
p=.77 
r=.17 
p=.77 
r=.15 
p=.77 
FPQ: medical  
r=-.13 
p=.88 
r=-.03 
p=.88 
r=-.11 
p=.88 
r=-.08 
p=.88 
r=-.22 
p=.59 
r=-.01 
p=.95 
r=.25 
p=.59 
r=-.02 
p=.95 
1 Correlation coefficients (r) and significance level (*p<.05, **p<.01, ***p<.001, †significantly lower than the respective correlation in 
sample 2) are reported. Degrees of freedom are depicted at the top. IPC-C: Internal, Powerful others and Chance scale. PRSS: Pain-
Related Self Statements Scale. FPQ: Fear of Pain Questionnaire. 
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Sample differences in the effects of controllability on pain and suffering 
There was no significant interaction of sample and controllability for pain intensity 
(F(1,49)=0.28, p=.60, d=.03), unpleasantness (F(1,49)=1.18, p=.28, d=.07), suffering 
VAS (F(1,49)=3.74, p=.06, d=.09) or PRISM ratings (F(1,49)=0.01, p=.93, d=.004). 
The correlation of chance–related locus of control with the difference in controllability 
ratings was significantly higher in sample 2 than in sample 1 for pain intensity (z= 
2.57, p=.01), pain unpleasantness (z=2.47, p=.01), suffering VAS (z=3.30, p=.001) 
and PRISM ratings (z=2.05, p=.04). The samples did not significantly differ in any of 
the correlations between the rating differences in pain intensity, pain unpleasantness, 
suffering VAS or PRISM with the subscales of the FPQ-III (all z<1.72, p>.08), PRSS 
(all z<1.27, p>.20) or IPC-I and IPC-P subscales (all z<1.40, p>.15).  
 
Physiological correlates of experimental controllability 
We found a significant increase of SCR during painful stimulation (F(2,50)=27.5, 
p<.001, d=1.93), a HR deceleration during painful stimulation (F(2,50)=14.01, 
p<.001, d=.29) and an anticipatory deceleration of corrugator EMG before the onset 
of painful stimulation (F(2,50)=9.89, p<.001, d=.14). None of the physiological 
measures differed significantly between controllable and uncontrollable trials. For 
further details on physiological data see supplementary material. 
 
Discussion and conclusions 
This study shows that control over pain primarily reduces the degree of perceived 
suffering. This effect was modulated by the subjects’ locus of control: The more 
participants attributed their behavior to chance, the greater was the reduction of 
suffering when they had control over their pain. Pain intensity and unpleasantness 
ratings, in contrast, were unaffected by control over pain. This effect was only present 
when the subjects showed a high personal involvement in the experiment initiated by 
an instruction that focused the person being able to stop the pain. In a second 
experiment, where the instructions referred to controllable trials as ‘stoppable by a 
button press’, suffering was not influenced by controllability. Here controllability 
increased unpleasantness ratings, while pain intensity and suffering remained 
unaffected. Interestingly the modulation by attribution to chance was inverse in this 
second sample: the more participants attributed their behavior to chance, the smaller 
was the reduction of suffering when they had control over their pain. 
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Controllability and its influence on suffering 
The finding that controllability reduces suffering extends the view of the impact of 
controllability on the pain experience by ascribing a key role to uncontrollability in the 
manifestation of suffering. According to Thompson [51], the effects of control depend 
on the meaning the individual ascribes to control, which matches the view that the 
transition from pain to suffering results when patients feel out of control, and that this 
transition is influenced by the meaning the individual ascribes to the pain (e.g. when 
chest pain is mistaken as a life threatening symptom by patients with a panic 
disorder) [15,29]. Thus, perceived controllability may act as an assurance that one 
will not face an event that is beyond the limits of endurance and suffering can be 
relieved by changing the meaning of the pain [3,14,42] to an experience that one can 
cope with. 
Our results could therefore shed a light on the inconsistencies of prior studies, which 
examined the relationship of controllability and pain perception by relying exclusively 
on the pain intensity and unpleasantness dimensions. Because prior studies did not 
assess pain-related suffering, it is not clear to what extent these measures implicitly 
related to suffering. Depending on the relevance of suffering for the given 
experimental setup, pain relief [7,39,57], no changes [20,27,47], or in some cases 
even increases in perceived pain [48,56] may be obtained. The choice of outcome 
measure is thus important for the detection of the effects of controllability. Suffering 
has recently been proposed as an outcome measure in patients with chronic pain in 
addition to pain intensity and unpleasantness measures because it encompasses 
aspects of helplessness, hopelessness and the feeling of being overwhelmed [3]. 
 
Controllability and its influence on pain unpleasantness 
In the second study, the pain unpleasantness ratings in the controllable condition 
were increased and controllability was not found to alleviate suffering. Testing for 
sample interaction effects showed that the effects of controllability on pain and 
suffering did not differ between the samples (see Figure 2). As reported above, 
increased pain ratings in response to controllability have been found before [48,56]. 
Our experimental design was similar to the one used in a study on brain mechanisms 
of pain controllability [57], but did not implement a button press at the end of the 
uncontrollable trials. This was included in the original study to account for motor 
responses in the brain. This missing button press at the end of the uncontrollable 
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trials may have induced a different attentional state as compared to the controllable 
trials. An attentive, but non-reactive awareness was previously shown to reduce pain 
unpleasantness [40]. 
 
Locus of control and suffering 
An external locus of control directed towards luck, fate or chance has been 
associated with maladaptive pain coping strategies [19] and higher levels of pain 
despite patient-controlled analgesia [28]. Patients with chronic pain who attributed 
pain to chance experienced pain more frequently and showed high pain intensity 
ratings [11]. Overall, chance locus of control might be associated with less physical 
activity, more medication abuse and higher interference of pain in daily life [11]. 
Internal locus of control, by contrast, has been associated with positive outcomes like 
lower pain scores, higher satisfaction and lower disability levels [18,28].  
In sum, although an internal locus of control seems to be a resilience factor against 
chronic pain [2,25], it does not seem to be associated with pain perception in 
experimental pain [57]. Rather, attribution to chance seems to lead to worse outcome 
expectations. Our results suggest that attribution to chance modulates the effects of 
control over pain on pain-related suffering. Fear of pain or pain catastrophizing did 
not modulate the effects of control, which implies a specific effect of the attribution to 
chance. 
In study 1, higher attribution to chance led to greater reduction of suffering when pain 
could be controlled. However, in contrast to these findings, we found the inverse 
relationship in our second experiment. The two studies differed in the instructions 
given to the participants. It may be that subjects with a high attribution to chance 
usually do not perceive experimental pain as controllable, but may have overcome 
their general feeling of uncontrollability after the explicit announcement of control as 
a personal capacity in study 1. This, however, cannot explain the contrasting findings 
of our second study. Future studies should therefore more stringently target the 
modulatory effects of instructions on the effects of pain controllability on suffering. 
Additionally cultural factors should be considered, as it has been shown that the 
influence of external locus of control on affective symptoms is weaker for collectivistic 
societies [17]. Moreover, the meaning of suffering differs between cultures and 
depends not only on the cultural background of the patient but also on the cultural 
background of the caregiver [21,36,55]. 
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Physiological correlates of experimental controllability 
In this study, neither corrugator EMG nor SCR or HR were affected by control over 
pain. This is in line with a study showing that changes in SCR were not associated 
with the failure to control pain [27]. This study, however, also showed that changes in 
HR were associated with the failure to control pain. We previously found that SCR 
and corrugator EMG, but not HR were associated with suffering [8]. Given the 
explorative nature of our hypothesis on physiological correlates of controllability 
effects and the sensitivity of those effects to the modulation by individual and 
contextual factors, there is a need for further research on this issue. This should 
address the effects of perceived and exerted control on physiological correlates or 
the modulatory effects of personality. 
 
Limitations 
The instructions in our experiment where not optimal for the use of the PRISM task. It 
therefore cannot be ruled out that this ambiguity affected other aspects of the 
experiment. However, as all reports of ambiguity referred to and were limited to, the 
PRISM rating, it is unlikely that our results were biased by misunderstandings of the 
instructions. A change of the instructions in a second sample did not yield any 
changes in the effects of control on the PRISM task. The PRISM task was developed 
and validated for the application in health issues like posttraumatic stress disorder 
[59], lung disease, psioriasis, breast cancer [60] or chronic urticaria [52]. The 
sensitivity of the PRISM task in an experimental setting with healthy individuals has 
not been tested and classical VAS measures seem to perform better in this task. 
 
Conclusion 
The present study demonstrates that controllability primarily affects suffering rather 
than pain severity or unpleasantness. In addition, this result helps to understand the 
previous inconclusive findings on the effect of controllability on pain. We propose a 
complex interaction between individual control beliefs and instructional context that 
influence the experience of suffering. Future studies should take these factors into 
account when studying the effects of controllability and assessing its significance in a 
clinical context. 
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SUPPLEMENTARY MATERIAL 
 
Physiological data 
We recorded physiological responses during an anticipation phase, on-blocks and 
off-blocks (see Figure 1a). Anticipation of pain triggers similar physiological 
responses as pain itself [5], and the anticipation of pain may influence the experience 
of pain itself [4]. To study the effect of pain (on-block) or the anticipation of pain 
(anticipation phase) we also recorded a phase without any stimulation or the 
anticipation of the same (off-block) at the end of each trial to have a baseline of 
physiological responses. Physiological responses have previously been divided into 
different components, which have also been related to different pain components. 
For example, HR responses to pain were related to physical pain intensity until 3 
seconds of pain onset, while after 6 seconds they were related to the perceived pain 
experience of the subjects [3]. We therefore checked HR and EMG responses for 
time effects before the main analysis. 
 
Recordings 
Raw EMG signals were filtered with a 20 Hz low cut-off, fullwave rectified and 
integrated (time constant: 10 ms) using a digital filter. When the EMG was split up 
into time bins of 1 second, we found a main effect of time for uncontrollable trials in 
the off-blocks (F(11,264)=5.62, p<.001, d=.16) and the on-blocks (F(11,264)=1.82, 
p=.04, d=.13), and for the controllable trials in the off-blocks (F(11,264)=4.46, p=.005, 
d=.20). There was no significant time effect for the anticipation phase (all 
F(5,120)<.84, p>.52, d<.03). As can be seen in Figure S1, these time effects can be 
split up into two phases (0-6 seconds and 6-12 seconds). These phases were 
therefore considered separately, when analyzing the EMG. Extreme values were 
excluded from the analyses (cut-off 2 SDs; 3.6% of the trials). All trials of the 
anticipation phases, on-blocks and off blocks were averaged per participant. 
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Figure S1: Time effect in the electromyogram of the corrugator presented in time-
bins of one second within each phase of a trial: lines show mean values, error bars 
depict the standard error of the mean of the corrugator EMG during anticipation 
phase (ANTI), On-blocks (ON) and Off-Blocks (OFF). Grey lines depict controllable 
trials, black lines depict uncontrollable trials. Asterisks show significant main effects 
within each block (anticipation, on-block, off-block) and condition (controllable, 
uncontrollable) with ***p<.001. EMG: electromyogram of the corrugator; ANTI: 
anticipation phase; ON: on-blocks; OFF: off-blocks; 
 
SCR amplitudes were quantified as the maximum response in the time window of 2–
6 s in the anticipation phase, the on-block and the off-block, and were converted to 
microSiemens (μS). This time window was chosen because it showed the largest 
responses during raw data inspection. SCR amplitudes below 0.05 μS were 
classified as zero responses. The data were transformed using a logarithmic 
transformation (log10(1+SCR)) and extreme values were excluded from the analyses 
(cut-off 2 SDs; 4.1% of the trials). To account for habituation effects during the 
experiment, nonlinear detrending was performed by fitting the data to an 1/ex 
function using the nonlinear least squares method in R [1]. For each subject an 1/ex 
function was fitted to the log-transformed original data. All further analyses were 
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performed with the residuals of the original data from this fitted function. All trials of 
the anticipation phases, on-blocks and off-blocks were averaged per participant. 
 
Figure S2: Time effect in the heart rate presented in time-bins of one second within 
each phase of a trial: lines show mean values, error bars depict the standard error of 
the mean heart rate during anticipation phase (ANTI), On-blocks (ON) and Off-Blocks 
(OFF). Grey lines depict controllable trials, black lines depict uncontrollable trials. 
Asterisks show significant main effects within each block (anticipation, on-block, off-
block) and condition (controllable, uncontrollable) with *p<.05 and **p<.01. HR: heart 
rate; ANTI: anticipation phase; ON: on-blocks; OFF: off-blocks; 
 
Raw ECG signals were filtered offline with a 20 Hz low cut-off digital filter. Beat 
detection was visually inspected and interpolated (added, removed or relocated: <1% 
of R-peaks), if necessary. When the HR was split up into time bins of 1 second, we 
found a significant main effect of time in the on-blocks (controllable: F(11,264)=9.40, 
p=.001, d=.23; uncontrollable: F(11,264)=7.78, p=.004, d=.21), in the anticipation 
phase (controllable: F(5,120)=4.23, p=.03, d=.11; uncontrollable: F(5,120)=4.01, 
p=.04, d=.11), in the off-blocks only for uncontrollable trials (controllable: 
F(11,264)=2.78, p=.08, d=.05; uncontrollable: F(11,264)=4.48, p=.01, d=.06), as can 
be seen in Figure S2, this time effect can be split up into three phases (0-3 seconds, 
3-6 seconds, 6-9 seconds), as was previously done by Möltner et al. [3]. These 
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phases were therefore considered separately, when analyzing the heart rate. Heart 
rate (HR) was calculated as mean HR before the stimulation (anticipation phase, 6 
seconds), during the stimulation (on-block, variable duration) and after each 
stimulation (off-block, 12 seconds). Extreme values were excluded from the analyses 
(cut-off 2 SDs; 4 % of the trials). All trials of the anticipation phases, on-blocks and 
off-blocks were averaged per participant. 
 
Statistical analysis 
For SCR, EMG and HR we examined the within-subject effects of block (on-block vs. 
anticipation phase vs. off-block), and controllability (controllable versus 
uncontrollable). For HR we additionally included the factor time (0 to 3 sec vs 3 to 6 
sec vs. 6 to 9 sec). Effect sizes for the ANOVAs are reported as Cohen’s d. We used 
pairwise post-hoc t-tests (false discovery rate, FDR [2] corrected) to compare the on-
blocks, off-blocks and anticipation phases. Effect sizes for the t-tests are reported as 
Cohen’s d. 
 
Results 
SCR showed a significant effect for block (F(2,50)=27.5, p<.001, d=1.93). Post hoc 
comparisons revealed that the SCRs were significantly higher during on- compared 
to off-blocks (t(24)=5.29, p<.001, d=1.03) and the anticipation phase (t(24)=6.80, 
p<.001, d=1.33), see Figure S3. The SCRs during the anticipation phase did not 
significantly differ from the SCRs during the off-blocks (t(24)=-0.03, p=.97, d=.006). 
There were no other significant main effects or interactions (all F<2.9, all p>.06, all 
d<.09). 
The EMG showed a significant main effect for block (F(2,50)=9.89, p<.001, d=.14) 
with post-hoc comparisons showing that EMG during anticipation phase was lower 
than during off- (t(24)=-4.57, p<.001, d=.93) and on-blocks (t(24)=-3.46, p=.003, 
d=.70). EMG during on-blocks did not differ significantly differ from the EMG during 
off-blocks (t(24)=-.55, p=.58, d=.11), see Figure S3. There were no other significant 
main or interaction effects for the EMG response (all F<2.38, p>.12, d<.04).  
HR showed a significant main effect for block (F(2,50)=14.01, p<.001, d=.29). Post 
hoc comparisons revealed that HR was significantly lower during on- compared to 
off-blocks (t(24)=-3.95, p=.002, d=.80) and the anticipation phase (t(24)=-3.55, 
p=.002, d=.72). HR during anticipation was significantly lower than during the off-
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blocks (t(24)=-3.21, p=.004, d=.65), see Figure S3. Furthermore, the HR displayed a 
significant main effect for time (F(2,50)=7.45, p=.008, d=.06). Post-hoc comparisons 
showed that HR was significantly higher in the first 3 seconds after onset, compared 
to seconds 3 to 6 (t(23)=-5.52, p<.001, d=1.12) and decreasing again in seconds 6 to 
9 (t(23)=-2.74, p=.01, d=.56). We furthermore found a significant interaction of time X 
block (F(4,100)=5.87, p=.01, d=.14), which represents the stronger heart rate 
deceleration during on- compared to off-blocks, especially 6 to 9 seconds after onset, 
see Figure S2. There were no other significant main or interaction effects for the HR 
(all F<2.04, p>.16, d<.02). 
 
Figure S3: Psychophysiology: Bars show mean values, error bars depict the 
standard error of the mean. Asterisks show significant post-hoc tests (corrected for 
multiple comparisons with the false discovery rate FDR) with **p<.01 and ***p<.001. 
(a) heart rate was lowest during on-blocks. During anticipation HR was already 
decreased. (b) Corrugator electromyogram was decreased during anticipation only. 
(c) Skin conductance responses increased during painful stimulation (on-blocks). 
SCR: skin conductance responses; EMG: electromyogram of the corrugator; HR: 
heart rate; ANTI: anticipation phase; ON: on-blocks; OFF: off-blocks; 
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3 GENERAL DISCUSSION 
3.1 Study 1 
Our healthy volunteers showed SIA when placebo was administered, as well as after 
THC or CBD administration. This is indicated by reduced pain ratings and increased 
pain thresholds after the stressor. However, neither THC nor CBD altered the SIA 
effect, and therefore the results do not support hypotheses 1.1 and 1.2. BOLD 
responses in the fMRI showed that the SIA effect was associated with increased 
brain activity in the ACC, thalamus and PAG after the stressor compared to before, 
independent of the administered drug. Those areas have previously been implicated 
in the descending inhibition of pain. Activity in the frontal pole, which was previously 
associated with preparatory responses to pain (Ploghaus et al., 1999), attention to 
pain and affective pain processing (Coghill et al., 2003), increased after the stressor 
in the THC and placebo condition, but not after CBD administration. Further, THC 
was associated with lower reductions of activity in S1, but not other areas of the 
descending pain pathway. CBD did not alter SIA-induced activity in any brain region 
that is involved in the descending inhibition of pain. Therefore the results do not 
support hypotheses 2.1 and 2.2. Additional analysis showed that THC, compared to 
the placebo condition, attenuated the habituation to a painful stimulus. Along with this 
habituation to painful stimulation, the activity in the MFG and MTG showed a greater 
reduction when a placebo was administered compared to THC. 
These results suggest that the endocannabinoid system is involved in modulatory 
mechanisms of pain, however, in a different way than expected. In the following the 
absence of SIA modulation by cannabinoid action is discussed, as well as the 
presence of modulation of habituation by cannabinoids. 
The absence of SIA modulation by different cannabinoid receptor agents contradicts 
rat studies, which demonstrated cannabinoid involvement in SIA (Connell et al., 
2006; Hohmann et al., 2005). These contradictory findings may have two possible 
explanations with different implications for pain therapy and basic research on the 
neurochemical mechanisms of pain: (1) Conclusions from rat studies on 
endocannabinoid-mediated SIA cannot be generalized to human pain pathways. (2) 
The SIA effect that we see in our study underlies a different mechanism than those 
seen in prior studies. 
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The first explanation may relate to the lack of SIA modulation by cannabinoids in 
study 1. It can however hardly explain the effects that we found on habituation to 
pain. These results indicate that there is indeed a cannabinoid-mediated pain 
modulatory mechanism that is preserved in humans. Further, the endogenous 
cannabinoid system is conserved throughout evolution from coelenterates to humans 
(Salzet, Breton, Bisogno, & Di Marzo, 2000). Therefore it also seems likely that 
cannabinoid function and neuronal pathways are preserved in humans. 
The second explanation is in line with the fact that all prior studies on 
endocannabinoid mediation of SIA used painful electric stimulation to induce stress. 
The original study, which proposed a non-opioidergic pathway for SIA has used 
continuous inescapable foot shock (3 minutes at 60Hz with 3 mA) to induce non-
opiodergic SIA (Lewis et al., 1980). Later studies adopted this procedure, changing 
only the stimulation intensity to 0.9mA, and confirmed an endocannabinoid mediation 
of this type of SIA (Connell et al., 2006; Hohmann et al., 2005). In our study we have 
used a continuous stressor as well, however not a painful stimulus but rather a 
cognitively demanding task. Moreover, we used electrical stimulation blocks to 
measure pain sensitivity before and after the stressor. During this painful stimulation 
we found a reduction of pain sensitivity. The administration of THC, a cannabinoid 
receptor agonist, attenuated this pain suppression. The electrical stimuli that we used 
to measure pain sensitivity might therefore have induced the same cannabinoid-
mediated pain suppression, which was found in animal studies using electrical stimuli 
to induce SIA. The second explanation, however, is not in line with the finding that 
opioid-mediated SIA is induced by intermittent stress, while non-opioid mediated SIA 
is induced by continuous stress (Lewis et al., 1980). We have used a continuous 
stressor, which by this rationale should induce cannabinoid-mediated SIA, while our 
intermittent painful stimulation should induce opioid-mediated SIA. However, previous 
data have shown that a continuous stressor, similar to the one we used, also induced 
opioid-mediated SIA (Flor et al., 2002) and supports our data which show that this 
type of SIA may be independent of cannabinoids. Furthermore, the stressor we used 
was 15 minutes long and therefore significantly longer than the 3 minutes that were 
used to induce non-opioid SIA in the study by Lewis et al. (1980). In the same study, 
30 minutes of stressful stimulation induced opioid-mediated SIA (Lewis et al., 1980). 
The painful stimulation in our study, with a total of ~2 minutes (10 times 11.76 
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seconds) of stimulation, resembles the duration of this non-opioid stress induction 
much better than our mental stressor. 
Habituation to repetitive painful stimulation is a form of non-associative learning and 
was found to be impaired in patients with chronic pain disorders (Valeriani et al., 
2003), whereas intact habituation seems to be a resilience factor for chronic pain. 
Central processing of habituation was confirmed in a study, which showed that pain 
attenuation was found at the arm contralateral to the stimulation site. This effect was 
not modulated by the systemic administration of an opioid receptor antagonist 
(Rennefeld, Wiech, Schoell, Lorenz, & Bingel, 2010). On the neuronal level, 
habituation to pain was accompanied by a reduction of activity in the medial 
prefrontal cortex, ACC, thalamus, S1, S2 and insular cortex (Becerra et al., 1999). A 
similar network of brain regions showed decreased activation during painful 
stimulation in study 1. So far no study has directly investigated the modulation of 
habituation to painful stimulation by cannabinoids. However, the cannabinoid system 
was shown to be involved in a number of learning processes: Cannabinoid agents 
were shown to modulate fear extinction in the hippocampus (Abush & Akirav, 2010). 
A well-established finding is also that cannabinoids modulate working and short-term 
memory (Ranganathan & D'Souza, 2006). In general, cannabinoid receptor agonists 
seem to impair memory formation, whereas cannabinoid receptor antagonists seem 
to reverse these deficits or act as memory enhancers (Riedel & Davies, 2005). In our 
study we showed that THC, a cannabinoid receptor agonist, impaired non-associative 
learning, here habituation to repetitive painful stimulation. This significantly adds to 
our understanding of learning mechanisms in pain processing. It is, however, an 
incidental finding and therefore needs to be replicated in another sample. Such 
studies should take special care with respect to timing aspects of the experimental 
procedures. For example, the low-frequent blood sampling in our study caused 
methodological limitations, which may be overcome by implementing continuous 
blood monitoring. 
3.2 Study 2 
The healthy volunteers in study 2 indicated that they suffered less during a 
controllable painful stimulation compared to an uncontrollable painful stimulation, 
while perceived pain intensity and unpleasantness were not different between the 
controllable and uncontrollable painful stimulation. Therefore the results only partly 
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confirmed hypothesis 3.1. The significant interaction between the effect of control on 
pain ratings and the type of rating indicate that the effect of control on the suffering 
rating was more pronounced than that on pain intensity and pain unpleasantness 
ratings. Therefore the results support hypothesis 3.2. Additional analyses showed 
that the ameliorating effect of controllability on suffering was stronger in subjects with 
a high chance-related locus of control. In a second experiment the instructions were 
changed from announcing controllability as a personal capacity (first experiment) to a 
technical procedure (second experiment). Analysis of the second experiment showed 
that suffering was no longer modulated by control and that the relationship between 
chance-related locus of control and the effects of control was inverse. Subjects with 
higher chance-related locus of control showed lower reductions of suffering when 
pain could be controlled than when pain was not controllable. Further, pain 
unpleasantness ratings were higher in the controllable condition as compared to the 
uncontrollable condition in the second experiment. 
These results have several implications. First, our data experimentally confirm 
theoretical work on suffering, such as the work of Cassell (1982), who postulated that 
controllability has a strong modulatory influence on suffering. This assumption has 
also been tested empirically in interview studies, where chronically ill patients 
(cardiovascular disease, diabetes, cancer, multiple sclerosis, lupus erythematosus 
and others) indicated that they suffered if loss of function was associated with loss of 
control over their lives (Charmaz, 1983). Along with this, an interview study with 40 
participants above 70 years of age identified lack of control as a general theme of the 
suffering experience in later life (Black & Rubinstein, 2004). Our study was the first to 
systematically vary controllability in an experimental setup to assess its effects on 
suffering. 
Second, the results of our data show that controllability was not associated with pain 
intensity and unpleasantness. It was previously shown that suffering is an 
independent component of the pain experience that can be assessed in experimental 
setups and is distinguishable from the pain intensity and unpleasantness dimensions 
(Brunner et al., 2017; Bustan et al., 2015). The present study now adds that suffering 
is also independently related to controllability as a specific aspect of the pain 
stimulation. 
Third, individual locus of control moderated the effect of control on suffering. A 
number of enduring beliefs have been associated with suffering (see Figure 2). In a 
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study with patients with myofascial pain dysfunction, for example, neuroticism was 
related to suffering in the presence of experimental as well as clinical pain, while no 
such relationship was found for the sensory aspects of the pain (Harkins, Price, & 
Braith, 1989). Additionally, fear of pain and private self-consciousness were 
associated with suffering in response to experimental pain stimulation in healthy 
volunteers (Brunner et al., 2017). Suffering is a highly individual experience and 
individuals will suffer under different conditions (Cassell, 1999; Edwards, 2003). 
Distressing events, such as a major illness may elicit suffering or not, depending on 
the meaning the individual gives to such events (Thompson, 1981). If the illness is 
associated with loss of important functions in the patients’ daily life, it will elicit higher 
degrees of suffering (Cassel, 1982; Cassell, 1999). A professional sprinter, for 
example, will most probably suffer from an injury which precludes his or her further 
career in sports. The same injury will induce comparable pain intensity and 
unpleasantness in an average person, however, this person may be suffering to a 
lesser degree if the injury does not impede daily-life functioning. Therefore individual 
beliefs and lifestyles may modulate suffering. The data of the current study did not 
only show that pain controllability alleviated suffering, but also that this effect was 
modulated by the individual beliefs of the person. In the case of our study the degree 
to which the individual tended to attribute events in his or her life to luck or fate. It did 
not matter for participants with a low chance-related locus of control if the external 
event (painful stimulation) was controllable or not, as they did not perceive this event 
as being controlled by external factors in the first place. On the other hand, 
participants who have a high chance-related locus of control, perceive external 
events (e.g. painful stimulation) as being controlled by external factors, which are out 
of their control. A clear indication of internal control changed the experience of the 
painful stimulation which then induced less suffering. 
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Figure 2: A theoretical framework, based on empirical findings, illustrating how 
suffering is related to stimulus properties of painful events, contextual setting, traits 
and other pain dimensions. Lines indicate positive (+) or negative (-) relationships, or 
modulatory (±) effects. Dashed lines in the bottom box indicate associations which 
need further empirical evidence. 
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3.3 Limitations 
Study 1 is limited by the systemic route of drug administration, which has the 
disadvantage of various areas of central, but also peripheral receptor binding. In 
animals the role of specific sites can be investigated by using microinjections into 
these areas (Connell et al., 2006; Hohmann et al., 2005), which allows for a 
dissociation of central and peripheral effects of drug administration. In humans, less 
invasive methods are preferred. We have used fMRI to identify the brain areas 
involved in cannabinoid modulation of pain. This, however, does not allow for 
conclusions about receptor binding in the brain areas identified, as indirect 
modulation by other brain areas might be responsible for the changes in BOLD 
response. In future human studies this drawback could be overcome by implementing 
methods with, for example, positron emission tomography (PET) to identify binding 
sites of the systemically administered drugs. Further we have used CBD in our study 
to down-regulate central cannabinoid signaling by acting as an inverse agonist at the 
CB1 receptor. The mode of action of CBD at the CB1 receptor is, however, still 
relatively unclear and may involve 5-HT and vanilloid receptor types (Maione et al., 
2011). The study might have benefitted from cannabinoid agents with a clearer 
receptor profile, such as SR141716A. However, SR141716A was shown to have 
severe side effects, such as severe mood disorders (Sam, Salem, & Ghatei, 2011). 
Another drawback related to pharmacokinetics is the relatively long experimental 
period without the assessment of THC and CBD concentration in the blood. We 
decided to use low frequent blood sampling to avoid unintended stressful events and 
because blood withdrawals were shown to confound BOLD signal changes (Kalisch, 
Elbel, Gössl, Czisch, & Auer, 2001). 
Study 2 could have benefitted from the prior development of a method to measure 
suffering in experimental setups. As there was no gold standard we used a VAS 
together with the “Pictorial representation of illness and self measure” (PRISM), 
where the latter seemed to be less suitable for experimental use. Further, study 2 
may not cover all aspects of the multidimensional phenomenon of suffering. For 
example, existential aspects of the suffering experience can hardly be addressed in a 
laboratory setup. Therefore the second study should be extended to clinical pain 
populations where controllability of the pain is central. 
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3.4 Conclusions and outlook 
Both studies contributed relevant findings related to endogenous mechanisms to 
regulate pain and suffering in humans, but also raised further questions. 
Study 1 found that the regulation of pain intensity and pain unpleasantness by 
habituation to repeated painful stimulation, but not SIA induced by a cognitive 
stressor, was modulated by THC. Cannabinoid based drugs become increasingly 
common in the treatment of chronic pain and the understanding of cannabinoid 
action becomes increasingly important. From the results of our study, it seems that 
THC does not increase the effects of endogenous pain inhibition by SIA, but rather 
impairs the habituation to pain. Future studies are needed to show if THC impairs the 
habituation to pain also in a clinical context. 
Study 2 found that controllability reduced suffering but not pain intensity or pain 
unpleasantness. It therefore sheds light on previous inconsistencies in studies on the 
role of controllability in pain perception. Study 2 failed to confirm these results in a 
separate sample, however it highlights the contextual setting and enduring beliefs as 
interesting modulators of controllability effects on suffering. 
Endogenous mechanisms to regulate pain remain a highly interesting field of 
research. The two studies show, that these mechanisms need to be addressed on 
multiple levels, reaching from the perceptual dimensions of the pain experience to 
neuronal and neurochemical mechanisms. Knowledge about the bodies’ own 
mechanisms to regulate pain, and an understanding of the modulation of those 
mechanisms, offers the possibility to strengthen them in patients who suffer from 
chronic pain and thereby offer pain relief for patients. 
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4 SUMMARY 
This dissertation presents two studies investigating stress-induced analgesia (SIA, 
study 1) and control-induced analgesia (study 2) as two endogenous mechanisms of 
pain control. In study 1 SIA was induced in 19 healthy volunteers after administration 
of Tetrahydrocannabinol (THC), Cannabidiol (CBD) and placebo. The SIA effect was 
evaluated by pain ratings and blood oxygen level dependent (BOLD) responses to 
suprathreshold painful stimulation, pain thresholds, BOLD responses and 
psychophysiological measures. The aim was to determine whether cannabinoids are 
involved in human descending pain control. The main result was that SIA, although 
successfully induced in all conditions, was not modulated by an exogenously 
administered cannabinoid receptor agonist or inverse agonist. However, after THC 
administration the habituation to painful stimulation was attenuated. This was 
accompanied by altered brain activation in the middle frontal gyrus and middle 
temporal gyrus. The results suggest that in humans, cannabinoids are involved in 
habituation to pain, but not in SIA. 
In study 2, 26 healthy volunteers were given painful stimulation in a controllable and 
an uncontrollable condition. The control-induced pain relief was assessed with ratings 
of pain intensity, pain unpleasantness and pain-related suffering. The aim of the 
study was to determine which pain dimension is affected by controllability of pain 
stimulation. The main result was that the exertion of control over pain reduced the 
experience of pain-related suffering while pain intensity and pain unpleasantness 
were not affected. Moreover, the effect on pain-related suffering was more 
pronounced in individuals with a higher general belief that their environment is 
determined by chance. The results suggest that control over a painful stimulus does 
not affect the classical pain dimensions of intensity and unpleasantness, but rather 
the suffering that is associated with them. 
The results of study 1 indicate that SIA induced by mental arithmetic tasks is not 
mediated via endocannabinoid pathways, whereas these pathways seem to be 
involved in other inhibitory pain systems. Study 2 demonstrates that control over pain 
alleviates the suffering rather than the pain itself. It therefore offers a therapeutic 
target in cases of terminally ill, were suffering but not pain can be avoided. A better 
understanding of behavioral, physiological and neuronal mechanisms underlying 
healthy human pain inhibition offers new targets for pain inhibition in chronic pain.  
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